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ABSTRACT 
 
Despite the use of potent modern immunosuppressive agents chronic rejection remains the leading 
cause of allograft failure after renal transplant. Historically T cells were considered to be the main 
pivot of rejection mechanisms; however, over the past decade the key role of B cells in allograft 
rejection has been much more fully described. Antibody mediated rejection [AMR] was first 
classified as a distinct entity in the Banff histological classification of allograft pathology as late as 
2001. This was a consequence of the demonstration of the complement split product C4d in renal 
allografts giving indirect evidence of humoral injury, along with the development of newer assays to 
detect circulating HLA donor specific antibodies [DSAs]; both of which were subsequently shown to 
be associated with reduced allograft survival. The development of solid phase technologies, in 
particular single antigen beads has introduced a readily available assay which can detect HLA DSA 
with high sensitivity and specificity. The benefit of routine application of such assays in renal 
transplantation is not known and is the principal question of this thesis; that is to establish if the 
detection of HLA DSAs will help in predicting rejection and allograft loss.  
 
Patients transplanted at Imperial College Renal and Transplant Centre were recruited into the 
studies. The underlying hypothesis is that donor specific antibodies identified by the more recently 
developed techniques are associated with inferior allograft survival, addressed in several related 
studies as follows: 
1.  Is C4d staining with no morphological features of rejection associated with risk of 
subsequent AMR and allograft loss? 
2. Are preformed DSA detected by single antigen beads in the setting of a negative crossmatch 
associated with inferior allograft survival? 
3. What is the relevance of de novo DSAs after renal transplantation? 
4. What is the clinical significance of DQ DSA and should consideration be given to DQ 
mismatching in deceased organ allocation? 
5. Do outcomes in patients with ACR with a humoral component differ when compared to 
those with pure ACR when treated in a uniform manner? 
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A summary of the results is as follows: 
1. C4d in the absence of histological features is not associated with AMR. However, patients 
with acute tubular injury who have DSA are at risk of subsequent AMR. 
2. Patients with preformed DSA are at significant risk of AMR and allograft loss and as such 
antibodies detected by single antigen beads alone pre-transplant should be considered a 
relative contraindication to transplantation. 
3. Patients who develop de novo DSA are at risk of AMR, transplant glomerulopathy [TG] and 
allograft failure. Routine testing for the detection of DSA may allow the potential to 
augment immunosuppression in order to improve outcomes. 
4. DQ DSA are the most common DSA detected after transplant and are associated with 
inferior allograft outcomes. Patients mismatched at both DR and DQ alleles are at risk of 
developing DQ DSA. Algorithms incorporating the level of DQ mismatch might reduce DQ 
DSA formation and therefore improve long term allograft survival. 
5. Patients with ACR with a humoral element are at risk of subsequent AMR, TG and graft 
failure. Such patients might benefit from more aggressive therapies than those targeted at 
ACR alone.  
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Introduction 
 
Renal transplantation is the treatment of choice for patients with end stage renal failure with 
regards to both patient survival and quality of life [Thiruchelvam et al, 2011]. Unfortunately there 
remains a shortage of organs to meet demand; there are currently 6475 patients on the waiting list 
for a kidney transplant in the UK and they can expect to wait on average 1110 days [NHSBT, 2012] 
before receiving a transplant. 
The use of current induction therapies and potent immunosuppression regimens, along with careful 
immunological selection of transplant recipients and successful treatment of acute rejection has 
meant improvement in short term allograft survival over the past decades. However, long term 
allograft survival has not improved [Meier-Kriescheet al, 2004; El-Zoghby et al, 2009], with the 
average lifespan of a kidney transplant being 8-15 years depending on the type of donor [NHSBT, 
2012]. Chronic antibody mediated rejection remains the leading cause of allograft failure [Sellares et 
al, 2012; El-Zoghby et al, 2009]. 
Understanding the pathogenesis of antibody mediated rejection is important in order to identify the 
risk factors for its development. Identification of patients at risk can potentially offer an opportunity 
for prevention and intervention in order to reduce its occurrence. 
In this thesis the role of donor specific antibodies in the development of antibody mediated rejection 
and allograft failure is examined. Risk factors associated with their development and associated risk 
of inferior allograft outcomes are considered, in the hope that this will allow the opportunity to try 
and prevent/minimise the risk of the development of donor specific antibodies in the future.  
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CHAPTER 1 Transplant Immunology 
 
1.1.1 The major histocompatibility complex and its gene products 
 
The discovery of a genetic impediment to organ transplantation developed from work carried out on 
tumour immunobiology in mice. When tumours were transplanted from one mouse to another in 
order to enable longer study than a life span of an affected mouse, it was found that the tumour did 
not grow but was rejected [Gorer 1937]. This phenomenon was also seen when healthy tissue was 
transplanted, except when the tissue was transplanted into highly inbred mice [Gorer 1955]. The 
genetic influence of tumour and tissue survival was found to be confined to a single genetic locus 
which was termed the ‘histocompatibility locus’ and named H-2 from the original mouse studies 
[Snell 1951]. This major histocompatibility complex was also identified in humans and its products 
were called human leucocyte antigens [HLA]. HLA antigens are fundamental in providing protection 
against pathogens but are also pivotal in the success of transplantation. 
The MHC region is located on the short arm of chromosome 6 and spans 3.6 mega base pairs. Within 
the complex, three separate regions, class I, II and III are distinguishable as represented in figure 1.1. 
The MHC is highly polymorphic, with HLA-B being the most polymorphic gene in the human genome 
[Mungall 2003].  
 
Figure 1.1. A simplified map of the major histocompatibility complex on chromosome 6p21, showing 
the genes arranged in three classes.   [Taken from Kelly M A et al. Mol Path 2003;56:1-10] 
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The class III region does not contain any of the HLA genes, however it does encode for numerous 
proteins and cytokines associated with the immune response. These include complement 
components, tumor necrosis factor and heat shock proteins.  
 
1.1.2 HLA class I antigens  
Each HLA class I antigen is composed of an α heavy chain (≈45kDa) and a β light chain (≈12kDa). The 
class I region of the MHC encodes the α heavy chains of the class I antigens, mainly HLA –A, -B and –
C but also –E, -F and –G. Whilst the β light chain or β2-microglobulin is encoded by a gene on 
chromosome 15 and is monomorphic [Marsh, 2000]. A diagramatic representation of the class I 
antigen is seen in figure 1.2. Class I antigens are expressed on all nucleated cells in the body. Class I 
HLA present endogenous peptides, including viral proteins, which have been processed by the 
endoplasmic reticulum to CD8+ T cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    
 
Figure 1.2.  Schematic representation of the HLA class I antigen 
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 1.1.3 HLA class II antigens  
Class II antigens are also composed of a heavy α and a light β chain, both of which are encoded by 
genes in the MHC complex. The α chains are ≈33-35kDa and the β chains are ≈26-28kDa. The main 
class II antigens are HLA –DR, -DQ and –DP along with the less polymorphic HLA –DM and –DO. 
Unlike the class I antigens, the polymorphism of class II antigens is derived from both chains in DQ 
and DP antigens. However DR antigens have an invariant α chain with a polymorphic β chain, which 
is complicated further by the fact that there are several functional β chain genes which can be 
expressed simultaneously, with a DRB1 gene encoding one β chain whilst another being encoded by 
a separate DRB locus [Marsh, 2000]. A diagramatic representation of a class II antigen is seen in 
figure 1.3. A further major difference between class I and II antigens is their expression: class II 
antigens are only expressed on antigen presenting cells, namely dendritic cells, macropahges and B 
cells. However their expression may be induced on other cells as a result of an inflammatory 
response. Class II HLA present exogenous peptides by the lysosomal route [pathogens within 
phagocytic cells] to CD4+ T cells.  
 
 
 
 
 
 
 
 
 
 
 
 
   
             
 
    
 Figure 1.3.  Schematic representation of the HLA class II antigen 
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1.1.4 Minor histocompatibility antigens 
 
Endogenous proteins on recipient cells that are genetically polymorphic and can give rise to an 
immunological response to the donor are termed minor histocompatibility antigens. Although 
important in bone marrow transplantation [Gloumy et al, 1996], their role in solid organ 
transplantation and particularly renal transplantation is not well described [Dierselhuis et al, 2009]. 
Rejection can occur in recipients receiving a ‘HLA identical’ kidney, which suggests that minor 
histocompatibility antigens might have a role to play [Cecka, 2004]. Minor histocompatiblility 
antigens may be encoded autosomally or on the Y chromosome. The impact of the latter has been 
better studied. To answer the question of whether female recipients of male donor kidneys are at 
increased risk of rejection, Gratwohl and colleagues respectively analysed a large cohort and found 
that there was an increased risk of allograft failure in male into female kidneys than any other 
gender combination [Gratwohl et al, 2008]. Regarding autosomal minor histocompatibility antigens, 
one large study into their effect in transplants matched at the major histocompatibility antigens, 
found no risk of rejection or increased allograft failure in the ‘minor’ mismatched group [Heinold et 
al, 2008]. However work into minor antigens is by no means conclusive and should be the focus of 
further work. Non-HLA antigens will be discussed later in the chapter. 
 
 
1.1.5 Methods of HLA typing 
Methods of HLA typing have evolved over time and consequently more HLA alleles are continuously 
being identified. Currently over 7000 HLA alleles are recognised [IMGT/HLA database]. Typing 
initially was undertaken using serological methods but has since been superseded by molecular 
methods, which are undergoing constant refinement. Serological testing involved using sera from 
multiparous women and incubating the antibodies with lymphocytes of certain HLA types [Marsh]. 
Serological methods are still useful in determining whether a HLA allele detected by molecular 
methods is expressed [Elsner et al 2004].  
The development of the polymerase chain reaction (PCR) has enabled rapid HLA typing with high 
resolution [Middleton, 1999]. Although all based on PCR amplification of HLA genes, there are a 
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number of different techniques used [Howell et al, 2010; Dunn, 2011]. These include: PCR with 
sequence specific primers (PCR-SSP), PCR with sequence specific oligonucleotide probes (PCR-SSOP) 
and PCR with sequencing based typing (PCR-SBT). The principle behind PCR-SSP is that amplification 
of DNA with a particular primer depends upon the presence of a particular allele. With PCR-SSOP, 
following amplification, a labelled sequence specific oligonucleotide probe is added and binds only if 
the sequence matches. PCR-SBT gives the highest resolution of all the techniques and involves 
amplification of specific coding regions with subsequent amplicon sequencing. 
Currently for renal transplantation, typing at the HLA –A, -B and –DR loci only are required for 
allocation purposes in the UK and usually to the split specificity level. HLA splits are 2 closely 
structured HLA antigens which have been defined by more sensitive typing methods, and together 
they compose a parent antigen or ‘broad’ specificity level. With the advent of single antigen beads, 
and the association of class II DSA and chronic rejection [Pollinger et al, 2007], especially DQ donor 
specific antibodies, typing might need to be broadened prior to transplantation in order to 
determine risk.  
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1.2 Allorecognition and effector mechanisms 
 
Allograft rejection remains the leading cause of allograft failure following renal transplantation. 
Historically rejection has been considered in terms of its timing (hyperacute, acute or chronic) or the 
putative primary immunological mechanisms (cellular or humoral). It is likely that multiple non-
mutually exclusive pathways play a role in the rejection process which includes the innate along with 
the adaptive immune response, and incorporates both cellular and antibody effector processes. The 
following is a description of allorecognition along with the subsequent effector mechanisms. 
 
1.2.1 Allorecognition 
  
The recipient’s T lymphocytes can recognise donor alloantigens by two major pathways as shown in 
figure 1.4. Direct allorecognition is the predominant pathway initially, when donor APC’s are still 
present and can present alloantigen directly to recipient T cells [Janeway et al, 2001]. The indirect 
pathway resembles the normal immune response to antigens. Donor antigens from the graft and are 
taken up by recipient APCs and are presented to recipient T cells [Janeway et al, 2001]. More 
recently a third ‘semi-direct’ pathway has been described, the basis of which is that recipient APC 
can present donor peptide using both donor and recipient MHC [Afzali et al, 2008]. Recipient MHC 
can obtain donor intact MHC by cell to cell contact or following its uptake after its release in small 
vesicles by the donor APC cell. The recipient T cells than may be stimulated either directly by the 
donor MHC on recipient APC or indirectly by recipient MHC on recipient APC. Evidence for this 
phenomenon in vivo has just been published [Brown et al, 2011]. 
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Figure 1.4: Diagrams showing mechanisms of allorecognition 
a.  Direct allorecognition 
 
  
  
 
 
b.  Indirect allorecognition 
 
 
  
  
Donor APC 
Recipient T cell 
Recipient APC 
Recipient T cell 
Donor peptide antigen 
Donor peptide antigen 
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c. Semidirect allorecognition 
 
  
 
 
 
 
 
 
1.2.2 Role of T cells in rejection 
 
Antigen is presented to T cells in the context of a MHC-antigen complex. In general class I HLA 
antigens present intracellular proteins to CD8+ cells, whilst class II HLA antigens present extracellular 
proteins to CD4+ cells. In order to become activated the T cell requires interaction between the 
MHC-antigen complex and the TCR and also a co-stimulatory signal. In the absence of a second signal 
T cells become anergic. Co-stimulation is achieved by the surface molecules on APCs. Two B7 
molecules, CD80 and CD86, on the APCs bind to the CD28 molecule on the T cell. A further ligand on 
the T cell, CTLA-4, when bound either of the B7 molecules appears to down regulate the immune 
response [Walunas et al, 1998]. A further co-stimulatory molecule on APCs is CD40 and its 
Recipient APC 
Donor peptide antigen 
Donor MHC 
Recipient T cell 
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corresponding ligand CD40L (or CD154) [Li et al, 2009] with other, newer signal pathways having 
been decribed, for example the T-cell immunoglobulin mucin protein 1.  
Once activated, T cells proliferate and differentiate into subgroups, each with their own cytokine 
profile and effector function. Type 1 helper T cells produce interleukin-2 (IL-2) and interferon gamma 
(IFN-γ) and mediate the cellular immune response. Type 2 helper T cells facilitate the humoral 
response with production of cytokines providing B cell help, namely IL-4, IL-5, IL-10 and IL-13. Th17 
cells are thought to mediate rejection and produce IL-17, IL-21 and IL-22 [Heidt et al, 2010]. 
Mechanisms of allograft injury by T cells is via cell mediated cytotoxicity and effects of cytokines. In 
addition to the T cells which promote immune responses, a subgroup of T cells, regulate or control 
the response, T regulatory cells or Tregs.  
 
1.2.3 Role of the innate immune system in rejection 
 
Cells of the innate immune system have been shown to have an impact on allograft outcomes 
[Murphy et al, 2011]. This has also been shown clinically by the types of cells seen infiltrating 
rejecting allografts following alemtuzumab induction [Kirk et al, 2003]. The cells of the innate 
immune system most studied are NK cells, dendritic cells, macrophages and mast cells. The role of 
these cells is variable; they can act as APCs, produce cytokines and act as inflammatory cells [Liu et 
al, 2010]. An interesting study by Hirohashi et al, has shown that NK cells may play a pivotal role in 
chronic rejection. They found that in mice with donor specific antibodies, NK cells were necessary in 
order to produce the vasculopathy of chronic rejection independent of complement [Hirohashi et al, 
2012].  
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1.3 B cells 
 
 
1.3.1 B cell development 
 
 
The majority of B cells are produced in the bone marrow, while a minority of B cells are developed 
during fetal life and are found in the peritoneal and pleural cavities. The former are often referred to 
as B2 cells and the latter B1 cells. B1 cells form part of the innate immune system and produce low 
affinity natural antibody independent of T cells. B1 cells are characterised by the CD5 molecule on 
the cell surface.  
 
Central B cell development 
 
B2 cells originate in the bone marrow from pluripotent haemopoietic stem cells, which under the 
influence of cytokines develop into pro-B cells. Pro-B cells express Pax-5 (a master transcription 
factor) along with RAG1 and RAG2 which catalyse D-JH rearrangements within the immunoglobulin 
heavy chain loci. Pro-B cells also acquire the surface expression of CD19 and HLA class II molecules. 
The next stage in B cell development is the pre-B cell stage in which a complex consisting of a Ig 
heavy chain and ‘surrogate’ light chains is expressed. Other cell markers which appear at this stage 
of development are: CD20, which regulates cell cycle progression [Tedder 1994], CD40 which 
regulates immunoglobulin class switching [Durie 1994] and CD22 which inhibits BCR signalling 
[Nitschke 2004]. From here the pre-B cells undergo light chain gene arrangement and proceed to 
express surface IgM to form an immature B cell. These B cells then undergo central selection based 
on the expressed BCR [B cell receptor]. B cells whose receptors bind with high affinity undergo 
apoptosis or undergo further light chain rearrangements [Louzoun 2002]. Under 10% of formed 
immature B cells in the bone marrow survive this process and leave to the periphery [Brahim 1970].  
 
 
Peripheral B cell development 
 
Once released from the bone marrow, mature B cells circulate lymphoid tissues until they encounter 
antigen. If B cells receive co-signals from antigen specific T cells they migrate to the germinal centres 
where, with T cell help, they undergo class switching and affinity maturation and differentiate into 
memory B cells and plasma cells. Such plasma cells are long lived and survive for months. Plasma 
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cells do not express typical B cell markers but are characterised by the presence of the CD38 
molecule which is also present on thymocytes, immature myeloid cells and haematopoietic stem 
cells. Activated B cells which do not receive T cell help develop into short lived plasma cells (weeks), 
which secrete low affinity IgM antibodies as they do not undergo class switching. Memory cells are 
phenotypically like resting mature B cells, that is they express the surface molecules CD19, CD20, 
CD40, Fc gamma receptor II and MHC class II molecules. Memory B cells on re-exposure to antigen 
can generate plasma cells rapidly. Memory cells are extremely long lived and can survive for years.  
 
1.3.2 B cell activation 
 
B cell activation requires two signals. Different types of antigens may activate B cells and can be 
broadly divided into thymus dependent (TD) and thymus independent antigens (TI). The former 
account for the majority of protein and glycoprotein antigens and requires T cell help. TD antigens 
activate B cells by being processed by the B cell and presented on the MHC class II molecule to an 
activated T cell. A second signal is then provided by the interaction of the CD40 molecule on the B 
cell and the CD40 ligand on the T cell. TI antigens can be further subdivided into TI-1 and TI-2 
antigens. TI-1 antigens, for example bacterial lipopolysaccharides, are also known as mitogens and 
stimulate B cells to undergo proliferation and differentiation. At high concentrations of antigen 
these B cells produce polyclonal antibodies and such activation does not produce memory B cells. TI-
2 antigens, for example streptococcus pneumonia, activate B cells by cross linking of 
immunoglobulin receptors but also require non-cognate T cell help in order to produce antibody. 
 
 
1.3.3 B cell homeostasis  
 
The TNF-related cytokine BLyS [BAFF] is central to B cell homeostaisis and survival. There are 3 BLyS 
receptors: TACI (transmembrane activator I and calcium-signalling modulator and cyclophilin ligand-
interactor), BCMA (B cell maturation antigen) and BR3 (BLyS receptor 3 or BAFF receptor). BLyS 
exists in both membrane and soluble forms and is produced by neutrophils, monocytes, 
macrophages and dendritic cells. Another cytokine, APRIL is also involved in B cell survival and is 
produced by dendritic cells and osteoclasts. BR3 only binds BLyS and not APRIL.  
Animal models have shown that over expression of BLyS is associated with B cell autoimmune 
disease, conversely the use of a BLyS monoclonal antibody has demonstrated a blunting of 
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autoimmunity [Kalled 2005, Marino 2009]. This association has also been shown clinically in patients 
with SLE [Navarra 2011]. 
Treatment with rituximab is associated with an increased level of BLyS with B cell reconstitution, 
which has been seen with rituximab usage in both autoimmunity and also transplantation [Zarkhin 
2009]. Enhanced levels of BLyS have also been seen in transplant recipients induced with 
alemtuzumab which depletes both T and B cells [Bloom 2009]. Furthermore, it has been shown that 
increased BAFF expression after transplant is associated with both anti-HLA antibodies and antibody 
mediated rejection [Xu 2009]. However, a more recent study has shown that BAFF is associated with 
the expansion of IL-10 producing B cells, which are shown to have regulatory properties [Yang 2010].  
 
1.3.4 Role of B cells in rejection 
 
The key role of B cells in allograft rejection has been increasingly recognised over the past decade, 
following decades where T cells alone were considered pivotal to the rejection mechanisms. It is 
now accepted that T and B cells are inextricably linked in the pathogenesis of allograft rejection. B 
cells are involved in both the initiation and effector mechanisms of rejection; their role is outlined 
below. 
1. B cells are effective APCs and present antigen to CD4+ T cells. Also, B cells provide co-
stimulatory signals via expression of a number of molecules (B7, CD40, and OX40L), which 
enable T cell activation. Whilst alloreactive T cells can be activated in the absence of B cells, 
differentiation into memory T cells is impaired [Ng 2010]. Conversely, CD4+ T cells are 
required for B cell antibody production and isotype switching from IgM to IgG [Steele 1996]. 
 
2. B cells produce pro-inflammatory cytokines IL-6, interferon γ and lymphotoxin α. 
 
3. When B cells are activated they proliferate and differentiate into plasma cells which secrete 
antigen specific antibody. The period after initial B cell exposure to antigen until antibody is 
produced by plasma cells is 4-10 days and primarily results in the IgM antibody isotype. This 
contrasts with antigen re-exposure where there is rapid production of antibody, mainly IgG. 
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1.4 Antibody  
 
1.4.2 Antibody structure 
 
Each immunoglobulin molecule consists of 4 polypeptide chains, 2 heavy chains and 2 light chains 
linked together by disulphide bonds as shown in figure 1.5. Each chain can be divided into a variable 
and constant region. The variable region comprises the antigen binding site, whilst the constant 
region determines the immunoglobulin isotype. 
 
 
 
 
 
 
   
 
 
 
  Figure 1.5.  Structure of an antibody molecule 
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1.4.2 Antibody isotypes 
 
The protease papin can cleave the antibody molecule into 3 fragments; 2 Fab fragments [Fragment 
antigen binding] and the Fc fragment [Fragment crystallisable]. The Fc fragment contains part of the 
constant region of the heavy chains which differs between the isotypes and is the region which 
interacts with effector cells and molecules. There are 5 main different heavy chains; gamma (γ), 
alpha (α), mu (μ), epsilon (ε) and delta (δ) which correspond to the major classes of 
iummunoglobulins IgG, IgA, IgM, IgE and IgD respectively. In humans IgG can be further subdivided 
into subclasses IgG1, IgG2, IgG3 and IgG4 and IgA into IgA1 and IgA2. 
 
1.4.3 Antibody function 
 
Antibodies protect by a number of different mechanisms. They can neutralise a pathogen by binding 
to its surface and prevent it from entering cells. They also cause opsonisation, where binding to the 
pathogen enables recognition of the Fc receptors on phagocytic cells. Also antigen-antibody 
complexes can activate complement. Table 1.1 is a summary of the functional differences between 
the classes and subclasses.  
 
Table 1.1. Function of the immunoglobulin isotypes [Taken from Janeway, Travers, Walport, 
Shlomchik. Immunobiology 5. Churchill Livingston] 
 
Functional activity IgM IgD IgG1 IgG2 IgG3 IgG4 IgA IgE 
Neutralisation + - ++ ++ ++ ++ ++ - 
Oponisation - - +++ * ++ + + - 
Sensitisation for killing by 
NK cells 
- - ++ - ++ - - - 
Sensitisation for mast 
cells 
- - + - + - - +++ 
Activates complement 
system 
+++ - ++ + +++ - + - 
 
*IgG2 can act as an opsonin in the presence of Fc receptors of a particular allotype, found in ~50% of 
white people. 
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1.4.4 Detection of HLA donor specific antibodies 
The most widely used methods of detecting pathogenic donor specific antibodies remain the cell 
based assays [Gebel et al, 2003], although the advent of solid phase techniques and in particularly 
the single antigen beads have resulted in assays so sensitive their relevance is not yet known, which 
is one of the starting points of this thesis. The various techniques available are briefly described 
below. 
The CDC (complement dependent cytotoxicity] crossmatch was the original test which 
revolutionised transplantation when presented by Patel and Terasaki in 1969 [Patel, 1969]. The basis 
of the cell based crossmatch is that any potential antibodies in the recipient’s serum are detected by 
exposing the donor antigens expressed on lymphocytes in vitro pre-transplantation. In the case of 
the CDC test, complement is added to the serum and lymphocytes, and if donor specific antibodies  
of the appropriate subclass are present then the complement cascade will be activated and result in 
lysis of the lymphocytes. The basic CDC test was made more sensitive by the addition of anti-human 
globulin (AHG) in order to detect low titre antibody [Johnson et al, 1972]. AHG is added prior to 
complement and binds to any antibody-antigen complex on the lymphocytes, therefore amplifying 
the response to complement by increasing the number of Fc receptors available. The flow cytometry 
assay was developed in order to enhance further the sensitivity of the pre-transplant crossmatch, 
and was able to detect low titre as well as non-complement fixing antibodies [Garavoy et al, 1983]. 
With the flow cytometry assay, fluorescein labelled anti-human IgG is incubated with the patient’s 
serum and donor lymphocytes. If there is any binding to donor specific antibodies, these will then be 
detected by flow cytometry. 
With solid phase techniques HLA molecules are bound either to plates (ELISA) or beads. Single 
antigen Luminex beads are the most sensitive method for detecting HLA antibodies [El Awar et al, 
2005]. The beads are bound with HLA molecules which may be of a single specificity or a mixture of 
HLA molecules which correspond to the single antigen and mixed screening beads respectively. The 
technique involves incubating test serum with the beads and if donor specific antibodies are present 
they bind to the bead, fluorescein labelled AHG is then added. Following this the beads are then 
passed through a dual beam laser, as each bead contains a unique fluorochrome, one laser picks up 
antibody binding and the other identifies the corresponding bead and therefore its HLA specificity. 
The advent of single antigen beads, which detect HLA antibodies with high sensitivity and specificity 
have enabled the use of the ‘virtual crossmatch’ [Amico et al, 2009].  
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Other technologies already established might become more widely used. This includes the HLA 
Matchmaker program, which involves a computer program which considers the structural basis of 
HLA molecules [Duquesnoy, 2011].  
 
1.4.5 Non-HLA antibodies 
 
Studies into HLA identical transplantation have shown that non-HLA immune responses play an 
important role in allograft rejection [Opelz et al, 2005]. However the extent to which non-HLA 
antibodies contribute to allograft failure and other forms of allograft injury is yet to be determined. 
Non-HLA targets are expressed on endothelial and epithelial cells and can be categorised into non-
HLA antigens and tissue specific autoantigens [Zhang et al, 2010]. Below is summary of studies into 
non-HLA antibodies in renal transplantation and their effect on outcomes. 
MICA and MICB 
The MHC class I-related chain A (MICA) and B (MICB) are the product of an HLA related polymorphic 
gene, which is located in close proximity to the HLA –B locus on chromosome 6 [Sumitran-
Holgersson, 2008]. MICA is expressed on monocytes, fibroblasts and endothelial cells but not on 
resting lymphocytes [Zwirner et al, 1999].  
Zou et al demonstrated that the presence of MICA antibodies at the time of transplantation is 
associated with graft failure in patients well matched at the HLA loci [Zou et al, 2007]. In a 
prospective study as part of the international workshop, Terasaki et al showed that patients with 
anti-HLA and anti-MICA antibodies who were followed up had a significant increased risk of allograft 
failure at 1 and 4 years [Terasaki et al, 2007]. A more detailed study has investigated the impact of 
MICA mismatching by determining MICA alleles, which also allowed for the identification of donor 
specific MICA antibodies [Cox et al, 2011]. They found that mismatching at the MICA allele level was 
a risk factor for de novo MICA antibody formation, which was subsequently associated with rejection 
and inferior allograft function.  
Anti-endothelial antibodies  
Anti-endothelial cell antibodies [AECAs] are a heterogeneous group of antibodies directed against 
various antigenic targets on the endothelium, they comprise both IgM and IgG antibodies [Bordron 
et al, 2001]. A multi-centre trial investigating the usefulness of a pre-transplant endothelial cell 
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crossmatch, showed that those patients found to have donor reactive AECA’s were at significant risk 
of rejection [Breimer et al, 2009]. The development of de novo AECA’s after transplant has also been 
shown to be associated with rejection [Sun et al, 2011].  
Tissue specific antibodies 
Vimentin is a non-polymorphic protein expressed in the cytosol of endothelial and vascular smooth 
muscle cells [Zhang et al, 2010]. Anti-vimentin antibodies have been studied in more depth in the 
context of cardiac transplantation. However, anti-vimentin antibodies have also been shown to be 
associated with renal allograft loss [Carter et al, 2005]. An interesting observation is the association 
between the preferential detection of anti-vimentin antibodies in recipients of non-heart beating 
transplants when compared with heart beating donors [Mi et al, 2005]. 
Angiotensin II type I receptors are located in the glomeruli along with the proximal tubules and 
vasculature [Zhang et al, 2010]. The gene encoding the receptor is located on chromosome 3 and a 
few polymorphisms of the gene have been described [Dragun, 2008]. AT1R antibodies have been 
found in cases of acute AMR in patients with no detectable HLA or MICA antibodies [Reinsmoen et 
al, 2010].  
 
 
1.5 Complement System 
 
1.5.1 Complement components 
The complement system incorporates a number of plasma proteins which form part of the innate 
and adaptive immune response. It is activated through 3 main pathways: classical (C1q binding 
pathogen surface/Ab-Ag complex), alternative (pathogen surfaces) and the mannan binding lectin 
pathway (binding of MBL to mannose containing carbohydrates on pathogens) along with other 
proposed mechanisms. Its main role regardless of the route of activation is opsonisation of 
pathogens, production of anaphylactoids, along with cell lysis from the formation of the membrane 
attack complex. A schematic diagram and description of the complement cascade is seen in figure 
1.6. 
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 1.5.2 Role of complement in renal allografts 
The demonstration by Feucht and colleagues of the complement split products C4d and C3d in 
peritubular capillaries [PTC] as indirect evidence of immunological activation highlighted the role of 
antibody in renal allograft rejection [Feucht , 1991]. As a consequence C4d was included into the 
Banff criteria of allograft rejection in 2001. 
There are 2 different methods used to detect C4d, which are indirect immunofluorescence [IF] using 
a monoclonal antibody on frozen tissue sections and immunoperoxidase using a polyclonal antibody 
on paraffin embedded tissue. C4d scoring is dependent upon the technique used, with IF being more 
sensitive, therefore focal C4d staining by immunoperoxidase may equate to diffuse scoring by IF 
[Seemayer, 2007; Solez, 2008]. C4d scoring is classified as negative, minimal with 0-10% staining of 
PTC, focal with 11-50% and diffuse with >50% of PTC staining.  
There have been numerous studies showing the predictive value of C4d positive staining in renal 
allografts, with C4d positivity being associated with poor outcome. Feucht’s group analysed the 
relevance of C4d deposition in 93 patients with early renal allograft dysfunction. There was a 
significant number of graft losses in the C4d+ group when compared with the C4d- group at 1 year, 
18/51 [42.9%] and 4/42 [9.5%] respectively, p=0.0027 [Feucht, 1993]. In a follow up study of 218 
patients, Lederer showed that C4d was strongly associated with alloantibodies. C4d positive 
allografts had an inferior survival to C4d negative grafts and they found that C4d positivity within 6 
months of transplantation gave the worse prognosis [Lederer, 2001]. Collins et al stained for C4d in 
16 biopsies from high risk patients with classical histological features of AMR along with DSAs and 
compared these with a control group comprising ACR, CNI toxicity and no abnormality. None of the 
ACR group was C4d positive or was found to have DSA, compared with all in the AMR group. It was 
concluded that C4d was a specific and sensitive marker of DSAs and antibody mediated injury 
[Collins, 1999]. Nickelait in their study looking at the impact on management of C4d positive 
patients, highlighted a small group with no histological features of rejection who did not require 
therapy. However the majority of C4d positive patients had morphological evidence of rejection. 
They also found that the C4d status of allografts could change within a matter of days to weeks 
[Nickelit, 2002]. Mauiyyedi’s group was the first to show that C4d staining was associated with DSA 
and specific histological features [Mauiyyedi, 2002]. These initial studies contributed to antibody 
mediated rejection being introduced to the Banff classification for the first time in 2001. Later 
publications have unanimously demonstrated that in ABO compatible grafts C4d is predictive of poor 
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outcomes and associated with donor specific antibodies [Haririan, 2009; Kedainis, 2009; Kayler, 
2008]. 
The relevance of focal C4d in comparison with diffuse staining remains controversial. Kayler and 
Haririan have both looked at the relevance of focal C4d using immunoperoxidase. Kayler found that 
focal C4d was associated with DSA, although found no difference in allograft loss between the 
diffuse, focal and negative groups [Kayler, 2008]. Haririan and colleagues showed that focal C4d 
staining had a comparable effective on graft survival than diffuse C4d. However they also showed 
that DSA status predicted allograft survival despite C4d staining [Haririan, 2009]. Using the more 
sensitive IF method, Kedainis showed that focal C4d was associated with circulating alloantibody and 
there was a trend for inferior graft survival in the focal group when compared to the negative group 
[Kedainis, 2009]. 
C4d is not always considered detrimental in renal allografts. Peritubular capillary C4d staining is 
often seen in ABO incompatible [ABOi] grafts in protocol and indication biopsies in the absence of 
histological features of rejection [Haas, 2006; Setoguchi, 2008]. Furthermore, in one study it was 
shown that C4d positivity was associated with less scarring than those ABOi grafts who were C4d 
negative [Haas, 2009]. The presence of C4d deposition with circulating anti-donor [HLA, blood group 
etc] with stable graft function and no other morphological features of rejection is coined 
accommodation [see section 1.7.3]. 
The relevance of C4d staining in the absence of rejection in ABO compatible graphs has not been as 
extensively studied, probably since C4d, when present, is often associated with features of rejection 
even in protocol biopsies [Mengel, 2005]. Only a few papers have highlighted patients with C4d with 
acute tubular necrosis ; Nickeleit in their analysis of 398 indication biopsies only found 3 patients 
with C4d+ ATN [Nickeleit, 2002], likewise Mauiyyedi found 2/20 patients with diffuse C4d showing 
ATN only [Mauiyyedi, 2002]. Dickenmann, in a retrospective study of ABO compatible transplants, 
looked at the outcomes of C4d positive indicative biopsies lacking features of rejection. Of 22 
patients studied, only 1 had diffuse C4d with 21 having focal C4d. 5 of the patients received 
augmented immunotherapy. They found there was no difference in allograft survival but there was 
an improvement in allograft function in those patients who received treatment.  
More recent advances in the role of complement in transplantation have come from the finding of 
its role in ischaemic reperfusion, intra-renal synthesis of C3 and enhanced complement gene 
expression in deceased donor kidneys and its subsequent effect on allograft outcomes. 
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MBL 
1.5.3 Complement cascade 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. The classical pathway is activated when C1q binds directly to the Fc portion of 
immunoglobulin or the pathogen which causes C1r to cleave and activate C1s. C1s in turn cleaves 
C4 into C4a and C4b, the latter which binds to the pathogen surface. C4b then binds C2 which is 
cleaved by C1s forming C3 convertase, which cleaves C3 forming the C5 convertase [C4b2a3b]. This 
cleaves C5 into C5a [anaphylactoid] and C5b which couples with C6,C7,C8 and C9 to form the 
membrane attack complex.  
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1.5.4 Non-complement fixing antibodies 
 
The role of non-complement fixing HLA antibodies in renal transplantation is yet to be fully 
appreciated. A potential drawback of detecting HLA antibodies by single antigen assays is that they 
do not differentiate between the different subclasses of IgG. It is known that the 4 subclasses of Ig G 
differ in their ability to fix complement, with IgG1 and IgG3 able to activate complement whilst IgG2 
and IgG4 subclasses are considered non-complement fixing [Heinemann et al, 2007]. The detection 
of non-complement fixing antibodies in the setting of rejection may be a result of class switching, 
with activated lymphocytes first secreting IgM antibodies followed by IgG 1/3 and then IgG 2/4 
[Malisan et al, 1996]. Further studies have shown that non-complement antibodies synergistically 
activate complement in combination with complement activating antibodies [Murata et al, 2007; 
Rahimi et al, 2004]. Also, HLA antibodies against class I HLA antigens on the endothelium may cause 
rejection by stimulating proinflammatory and proproliferation signals [Zhang et al, 2009]. Finally, 
antibodies have also been shown to activate NK cells, neutrophils and macrophages through their Fc 
receptors [Murata et al, 2007]. The mechanisms involved in chronic rejection may be different from 
those in acute rejection. Hirohashi et al, presented data from an animal study that class I HLA 
antibodies can cause chronic arterial lesions in cardiac transplants in the absence of complement 
[Hirohashi et al, 2009].  
 
1.6 Allograft rejection 
 
1.6.1 Definition of clinical rejection 
Thus far I have described the mechanisms behind allorecognition and the subsequent effector 
responses. Rejection can manifest clinically in numerous ways; from a rapid deterioration in allograft 
function with or without oliguria, to a more insidious decline in function with or without proteinuria. 
In fact, in the era of protocol biopsies it has been shown that despite histological evidence of 
rejection, there may be no clinical evidence of rejection with no allograft dysfunction or proteinuria, 
and this is defined as subclinical rejection. The limited evidence that exists on protocol biopsies 
suggests that even in the absence of allograft dysfunction, histological rejection should be treated 
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[Henderson et al, 2011]. For the purposes of this thesis, rejection is defined as biopsy proven 
rejection in the setting of allograft dysfunction. 
 
1.6.2 Banff classification of allograft pathology 
Renal transplant biopsies are widely classified according to the Banff criteria. The first meeting took 
place in Banff in 1991 and the official categorisation of allograft pathology was established in 1997 
[Racusen et al, 1999]. Since that time there have been continued updates of the classification as 
necessary, with working groups formed in order to address unmet needs, for example whether the 
use of molecular markers can or should be integrated into the classification [Sis et al, 2010].  
Table 1.2 is taken from the current classification [Sis et al, 2010]. There are six, non-mutually 
exclusive categories; normal, antibody mediated rejection, borderline rejection, T cell mediated 
rejection, interstitial fibrosis and tubular atrophy and ‘other’.  
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Table 1.2: Banff 97 diagnostic categories for renal allograft biopsies—Banff ’09 update [Sis et al, 2010] 
__________________________________________________________________________________________ 
1. Normal 
2. Antibody-mediated changes (may coincide with categories 3, 4 and 5 and 6) 
Due to documentation of circulating antidonor antibody, C4d and allograft pathology 
 
C4d deposition without morphologic evidence of active rejection 
C4d+, presence of circulating antidonor antibodies, no signs of acute or chronic TCMR or ABMR (i.e. g0, cg0, 
ptc0, no ptc lamination (<5 layers by electron microscopy), no ATN-like minimal inflammation). Cases with 
simultaneous borderline changes are considered as indeterminate 
 
Acute antibody-mediated rejection 
C4d+, presence of circulating antidonor antibodies, morphologic evidence of acute tissue injury, such as 
(Type/Grade) 
I. ATN-like minimal inflammation 
II. Capillary and or glomerular inflammation (ptc/g >0) and/or thromboses 
III. Arterial – v3 
 
Chronic active antibody-mediated rejection 
C4d+, presence of circulating antidonor antibodies, morphologic evidence of chronic tissue injury, such as 
glomerular double contours and/or peritubular capillary basement membrane multilayering and/or interstitial 
fibrosis/tubular atrophy and/or fibrous intimal thickening in arteries 
 
3. Borderline changes: ‘Suspicious’ for acute T-cell mediated rejection (may coincide with categories 2 and 5, 
and 6) 
This category is used when no intimal arteritis is present, but there are foci of tubulitis (t1, t2 or t3) with minor 
interstitial infiltration (i0 or i1) or interstitial infiltration (i2, i3) with mild (t1) tubulitis 
 
4. T-cell mediated rejection (TCMR, may coincide with categories 2 and 5 and 6) 
 
Acute T-cell mediated rejection (Type/Grade:) 
IA. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of moderate 
tubulitis (t2) 
IB. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of severe 
tubulitis (t3) 
IIA. Cases with mild to moderate intimal arteritis (v1) 
IIB. Cases with severe intimal arteritis comprising >25% of the luminal area (v2) 
III. Cases with ‘transmural’ arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells 
with accompanying lymphocytic inflammation (v3) 
 
Chronic active T-cell mediated rejection 
‘chronic allograft arteriopathy’ (arterial intimal fibrosis with mononuclear cell infiltration in fibrosis, formation 
of neo-intima) 
 
5. Interstitial fibrosis and tubular atrophy, no evidence of any specific etiology 
(may include nonspecific vascular and glomerular sclerosis, but severity graded by tubulointerstitial features) 
Grade 
I. Mild interstitial fibrosis and tubular atrophy (<25% of cortical area) 
II. Moderate interstitial fibrosis and tubular atrophy (26–50% of cortical area) 
III. Severe interstitial fibrosis and tubular atrophy/ loss (>50% of cortical area) 
 
6. Other: Changes not considered to be due to rejection- acute and/or chronic (For diagnoses see table 14 in 
(49); may include isolated 
g, cg, or cv lesions and coincide with categories 2, 3, 4, and 5) 
 
39 
 
1.6.3 Accommodation 
 
‘Accommodation’ in transplantation refers to the absence of effector immune mechanisms despite 
the presence of antibody against graft antigens. Most extensively studied in the field of 
xenotransplantation, it was first described clinically following ABO incompatible transplantation 
[Chopek et al, 1987]. It is proposed that accommodation may occur as consequence of either 
changes within the graft endothelium or the characteristics of the donor directed antibody. One 
mechanism by which the former may occur is by the upregulated expression of protective genes; 
A20, Bcl-2, Bcl-xL and heme oxygenase 1 [Bach et al, 1997; Salama et al, 2001].  
Whilst the beneficial effect of accommodation in ABOi transplantation is indirectly observed by the 
good outcomes, HLA incompatible transplantation is not associated with the same success 
[Montgomery, 2010]. There is however a vital difference between blood group antibodies when 
compared to HLA antibodies, the former being carbohydrates (as are xenoantigens) whilst the latter 
are proteins [Rose et al, 2012]. They differ in their immune response, carbohydrates elicit T-cell 
independent immune responses whilst proteins induce T-cell dependent mechanisms [Rose et al, 
2012]. Only one study has demonstrated potential accommodation in response to HLA antibodies in 
sensitised patients who underwent antibody removal pre-transplant. In a small study of 7 patients, 4 
patients had DSA returning post-transplant, with 3 of these patients demonstrating upregulation of 
Bcl-xL in the absence of acute rejection [Salama et al, 2001]. Further studies are required into the 
mechanisms of accommodation in HLA incompatible grafts. 
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Chapter 2 Materials and methods 
 
 
2.1  Patient selection 
Patients studied in the thesis were all transplanted at Imperial College Renal and Transplant Centre 
between 2005 and 2011. All patients receiving a kidney alone transplant against a negative 
crossmatch were included. All patients receiving an antibody incompatible graft, which we define as 
a kidney transplanted against an incompatible blood group or a positive flow or CDC crossmatch 
were excluded from the analyses.  Inclusion criteria for each of the individual studies are defined 
later in the thesis. The number of patients included in each of the studies differs slightly because of 
the different timepoints at which the analyses were carried out.  
 
2.2  Histocompatibility and Immunogenetics methods 
Crossmatch Techniques 
All patients studied were transplanted with a negative T and B cell CDC crossmatch and a negative T 
cell FCXM performed in the Histocompatibility and Immunogenetics [H&I] laboratory at Imperial NHS 
Trust. B cell FCXMs are not routinely performed in our laboratory as we have found they lack 
specificity, similar to the experience of other groups [Delgado et al, 2008; Riethmüller et al, 2010]. 
Detection of HLA donor specific antibodies 
The presence of anti-HLA antibodies were detected using LABScreen® mixed beads (One lambda, 
Inc) in the H&I laboratory. Patients with a positive screen had the specificity of their anti-HLA 
antibody identified using LABScreen® single antigen beads. Each anti-HLA antibody detected by the 
Luminex fluroanalyzer had its signal intensity recorded [by mean fluorescence index (MFI)]. A MFI of 
more than 300 was considered positive.  In patients who had more than one DSA detected, the 
individual MFIs of the separate DSAs present were summed for Class I and Class II separately in order 
to calculate the overall intensity level. Taylor et al. found that summing the MFIs of multiple 
antibodies improved the predictive value of Luminex [Taylor et al, 2009]. Our laboratory protocol is 
to type for HLA -A,-B,-Cw,-DRB1, DRB3/B4/B5 and -DQ antigens. Patients are typed for DQA and DP 
antigens when indicated. 
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2.3  Immunosuppression regimens 
All study patients received monoclonal antibody induction with either alemtuzumab [Campath-1H®, 
Cambridge, MA] 30mg perioperatively or Daclizumab [Zenax®, Roche Inc, NJ] 2mg/kg on day 0 and 
day 14. Maintenance immunosuppression in the alemtuzumab group was tacrolimus [Prograf®; 
Astellas Inc, Japan] monotherapy with an aim to achieve a mean trough level of 5-8ng/ml. 
Daclizumab treated patients received tacrolimus with a mean trough level of 8-12ng/ml along with 
mycophenolate mofetil [Cellcept®, Roche Inc, NJ] with a mean trough level of 1.2-2.4mg/l by HPLC-
MS [High performance liquid chromatography with tandem mass spectrometry].  
All patients received a week of steroids starting at the time of transplantation. Our steroid sparing 
protocol consists of methylprednisolone (500 mg) iv preoperatively, followed by prednisolone 
1mg/kg/day (maximum 60 mg/day), reduced to 0.5mg/kg/day (maximum 30mg/kg/day) on day 4, 
and then discontinued after day 7. 
Alemtuzumab [Campath-1H®] is a monoclonal anti-CD52 antibody which is increasingly used as an 
induction agent in renal transplantation [Sampaio et al, 2009; Cai et al, 2011]. The CD52 antigen is 
expressed on B and T lymphocytes, natural killer cells, macrophages, monocytes and neutrophils 
[Hale et al, 1990; Ambrose et al, 2009]. Following administration there is depletion of all affected 
mononuclear cells, with discordant recovery of the different cell types, T lymphocytes failing to fully 
replete even after long term follow up [Bloom et al, 2006]. Although initial hypotheses that such 
radical depletion would enable tolerance were unfounded [Kirk et al, 2003], it has allowed successful 
transplantation in the setting of minimal immunosuppressive regimens [Calne et al, 1998 and 1999].  
It has been reported that alemtuzumab is associated with an excess of antibody mediated rejection 
[AMR]. However these reports were limited to patients receiving calcineurin inhibitor [CNI] free 
immunosuppressive regimens [Knechtle et al, 2003; Flechner et al, 2005]. Randomised control trials 
assessing the efficacy of alemtuzumab and CNI monotherapy have shown results in allograft and 
rejection free survival that are equivalent to other standard regimens [Margreiter et al, 2008; 
Vathsala et al 2005; Thomas et al, 2007].  
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2.4  Histopathological methods 
All biopsy specimens were examined by light microscopy (haematoxylin and eosin, periodic acid-
Schiff, Jones methenamine silver and Sirius Red-elastin van Gieson), and classified by the 
histopathology department at Imperial NHS Trust using the Banff 07 Classification of Renal Allograft 
Pathology [Solez et al, 2008], as seen in table 1.2.  
Immunohistochemistry for C4d was performed by the histopathology laboratory on paraffin sections 
from all biopsies, using polyclonal rabbit anti-C4d antibody at 1/40 (Oxford Biosystems, BI-RC4D). 
The slides were subjected to 20 mins microwave antigen retrieval, then placed on the Biogenex 
i6000 autostainer. The Biogenex Non-Biotin detection kit was employed. Slides were counterstained 
with haematoxylin and cover slipped. C4d staining was quantified and classified using the scoring 
proposed in the Banff 2007 Classification of Renal Allograft Pathology [Solez et al, 2008]. Namely, 
C4d was classified as negative/minimal [C4d0 and C4d1 with peritubular capillary (PTC) staining of 
0% and <10% respectively], focal [C4d2 with PTC staining of 11-50%] or diffuse [C4d3, PTC staining 
>50%].  
Antibody mediated rejection (AMR) was diagnosed according to the Banff criteria (for Type II or Type 
III AMR – as discussed further in Chapter 5) when either there was focal or diffuse C4d staining or 
DSA positivity with any of the following histological features; capillary and/or glomerular 
inflammation or thromboses, in the case of type II AMR and arterial involvement in the case of type 
III AMR. 
 
2.5  Treatment of allograft rejection 
Biopsy proven acute cellular rejection was treated with 500mg iv methylprednisolone on 3 
consecutive days along with the introduction of mycophenolate mofetil [Cellcept®; Roche, Nutley, 
NJ] to achieve 12 hour predose mycophenoleic acid levels of 1.2-2.4mg/l measured by HPLC-MS. 
After intravenous steroids, oral prednisolone was started (30mg/day) and weaned to 10mg by 3 
months and continued thereafter. Patients had their tacrolimus dose adjusted if necessary in order 
to achieve a 12 hour trough level of 8-12 ng/ml. Antibody mediated rejection was treated as above 
with the addition of 5 to 10 plasma exchanges with an exchange volume of 50mls/kg (maximum of 
4.5l) and a total of 2g/kg iv immunoglobulin (Vigam®; Bio Products Laboratory, Hertfordshire, UK) in 
divided doses for every 5 plasma exchanges. 
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2.6  Statistical Analysis 
All statistical analyses in this thesis were performed using Medcalc version 10.4.3. Comparisons of 
means and frequencies of normally distributed variables were calculated using t-tests and chi-
squared/Fisher’s exact tests. Survival analysis was determined using Kaplan-Meier plots [Kaplan et 
al, 1958]. If more than two survival curves are compared the logrank test for trend in survival scores 
across the groups is performed.  Cox proportional regression plots were used for multivariant 
analyses. A p value of <0.05 was deemed statistically significant. 
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Chapter 3 Relevance of C4d with minimal histological changes 
 
 
 
3.1 Introduction 
 
Acute antibody mediated rejection [AMR] occurs as a result of antibodies directed against antigens 
expressed on endothelial cells, with or without complement activation [Teraskai, 2003; Solez et al, 
2008]. The classic histological features of acute AMR include neutrophils or mononuclear cells in the 
peritubular capillaries, glomerulitis, vascular thrombosis and fibrinoid necrosis [Racusen et al, 2003]. 
Peritubular capillary C4d deposition is a marker of antibody mediated injury [Feucht et al, 1991; 
Feucht et al, 1993]. The Banff criteria for acute AMR were first established in 2001 and included a 
category comprising the presence of C4d deposition, evidence of circulating donor specific 
antibodies [DSAs] with morphological evidence of acute tissue injury [Racusen et al, 2003]. The 
category of “acute tissue injury” includes acute tubular necrosis (ATN) with no other features (acute 
or chronic) of antibody mediated damage. The prognosis of C4d positive/DSA positive ATN without 
other features of rejection in antibody compatible allografts is not well established. Certainly it is 
accepted that C4d positivity with no histological findings of rejection is not associated with adverse 
outcomes in ABO incompatible grafts and furthermore it has been shown in that setting to be a 
protective finding at least in the short term [Haas eta l, 2006; Hass et al, 2009; Haas, 2010].  
There are no published studies which have looked specifically at the prognostic significance of 
indicative biopsies in antibody compatible renal allografts showing C4d positivity and ATN only, 
incorporated with DSA data. The purpose of this study was to determine the relevance of C4d+ATN 
in terms of subsequent likelihood of developing morphological features of antibody mediated injury, 
allograft dysfunction or allograft failure.  
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3.2 Methods 
Patients 
All indicative renal allograft biopsies of patients transplanted at Imperial College Renal and 
Transplant Centre between October 2005 and January 2011 were retrospectively studied. All 
biopsies with a histological diagnosis of ATN without prior rejection and subdivided patients on the 
basis of C4d positivity were identified. Patients with more than one biopsy with the described 
histology had their index biopsy defined in the C4d+ group as the biopsy with the strongest C4d 
staining and in the C4d- group as the first biopsy after transplant. The medical records of patients 
were then reviewed in order to clarify that there was no enhancement of immunosuppression 
following the biopsy until the end point was reached. As a result 7 patients were excluded as they 
subsequently received iv Ig for pyelonephritis or BK nephropathy on further biopsy and 1 patient 
went on to receive plasma exchange for recurrent FSGS. 48 patients were identified who were C4d+ 
with a histological diagnosis of ATN, the control group was the 123 patients who had ATN but were 
C4d negative. The baseline patient demographics are shown in table 3.1.  
Histological and immunological screening methods are as described in chapter 2. Table 3.2 shows 
the distribution by focal or diffuse C4d staining of the patients studied. 
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Table 3.1 Table showing patient demographics 
 
 
 
 
 
 
  C4d+ 
[N=48] 
 
C4d- 
[N=123] 
p value 
Gender Male 
Female 
 
36 
12 
 
97 
26 
0.73 
Age at transplant Years 
 
50.28 ± 13.40 47.94 ± 12.30 0.46 
Ethnicity Indoasian 
Afrocarribean 
Caucasian 
Other 
 
15 
5 
26 
2 
44 
19 
55 
5 
0.69 
Cause of ESRF Diabetes 
APKD 
GN 
Urological 
Other 
Unknown 
 
8 
7 
15 
2 
2 
14 
28 
11 
31 
7 
5 
41 
0.71 
Type of graft DD 
LD 
SPK 
 
30 
17 
1 
68 
45 
10 
0.97 
Graft number 1 
≥2 
 
44 
4 
108 
15 
0.59 
Sensitisation Non-sensitised 
Sensitised 
Preformed DSA 
 
36 
11 
1 
92 
19 
12 
0.15 
HLA mismatch Mean 
 
2.96 ± 1.73 3.64 ± 1.57 0.22 
Induction Alemtuzumab 
Daclizumab 
 
39 
9 
102 
21 
0.97 
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Table 3.2 Distribution of C4d scoring in C4d positive patients 
 
 
C4d scoring 
 
% PTC staining 
 
Number of patients [n=48 (%)] 
 
 
C4d2 
 
11-50% 
 
39 (81.3) 
 
C4d3 
 
>50% 
 
9 (18.8) 
 
 
3.3 Results 
 
171/800 [21.37%] patients were found to have at least one indicative biopsy with a histological 
diagnosis of ATN. Of these, 48 [26.97%] were found to have at least one biopsy with C4d positive 
(focal or diffuse) ATN, whilst 123 [71.93%] patients had C4d negative ATN only. The mean time to 
index biopsy after transplantation was 4.51 ± 8.36 months, with no difference in timing between the 
C4d positive and negative groups, p=0.75. The median follow up after the index biopsy was 30.38 ± 
15.62 months. 
 
Patient and allograft survival 
There was no difference in patient survival between the two groups. There were 5 patient deaths in 
the C4d- group and 1 death in the C4d+ group, p=0.52. Figure 3.1 shows a Kaplan Meier curve 
demonstrating no difference in death censored allograft survival between the C4d+ and C4d- groups, 
which was 93.7% and 90.1% respectively, p=0.45. At the end of follow up 3 grafts were lost in the 
C4d+ group compared with 12 in the C4d- group. The causes of allograft failure in the C4d+ group 
were non-compliance, rejection and progressive scarring in a marginal donor organ. In the C4d- 
group, 4 of the grafts were lost as a consequence of rejection, one complicated by macrovascular 
compromise. The other causes of failure were BK nephropathy, renal vein thrombosis, ureteric leak, 
immunosuppressive withdrawal, haemorrhage after renal biopsy and progressive scarring of 
unknown aetiology.  
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Figure 3.1 Allograft survival by C4d staining. There was no difference in allograft loss between the 
C4d+ and C4d- groups, 93.7% and 90.1% respectively, p=0.45. 
 
 
Rejection free survival 
Analysing all rejection types, 9 patients in the C4d+ group experienced acute rejection after the 
index biopsy compared with 25 in the C4d- group, p=0.80 as shown in figure 3.2. 1/9 [11.1%] of 
diffuse C4d+ patients had rejection which was comparable with 8/39 [20.5%] of the focal C4d+ 
group, p=0.86. When considering episodes of rejection by cellular and antibody components, again 
there was no significant difference. ACR free survival was 82.8% and 83.0% in the C4d- and C4d+ 
groups respectively, p=0.97. Whilst considering antibody mediated rejection, 11 of the C4d- group 
subsequently developed biopsy proven AMR compared with only 1 in the C4d+ group, p=0.11, as 
shown in figure 3.3. There was no difference in the development of transplant glomerulopathy 
between the two groups at the end of follow up, p=0.13, as shown in figure 3.4. 
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Figure 3.2 Rejection free survival by C4d status at time of index biopsy demonstrating ATN 
only. There was no difference in all rejection episodes between the C4d+ and C4d- groups, 80.9% 
and 79.0% respectively, p=0.80. 
 
 
Figure 3.3 AMR free survival post index biopsy of C4d positive ATN.  
There was no difference in subsequent AMR between the C4d+ and C4d- groups, 97.9% and 90.8% 
respectively, p=0.11. 
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Figure 3.4 Transplant glomerulopathy free survival post index biopsy showing C4d positive ATN.  
There was no difference in subsequent TG between the C4d+ and C4d- groups, 93.5% and 98.2% 
respectively, p=0.13. 
 
 
Allograft function 
At the time of index biopsy allograft function as determined by serum creatinine in the C4d- and 
C4d+ groups was 257.0 ± 172.8 µmol/l and 245.7 ± 179.5 µmol/l respectively, p=0.70. Function was 
compared at 1, 3, 6, 9 and 12months after the index biopsy as shown in figure 3.5. At no time point 
during the 12 months after the index biopsy was there a significant difference between the groups. 
 
Focal versus Diffuse C4d 
Analysis was then repeated in order to determine if there was an effect of focal when compared 
with diffuse C4d staining. There was no significant difference in terms of allograft survival, rejection, 
AMR or TG between the focal and diffuse groups as seen in figure 3.6. 
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Figure 3.5. Comparison of allograft function by serum creatinine [µmol/l]  
 
 
 
 
 
 
 
Figure 3.6 Allograft outcomes by C4d score 
 
 
3.6.1 Allograft survival by C4d score. There was no difference in allograft loss between the diffuse 
C4d+, focal C4d+ and C4d- groups at 100.0%, 92.3% and 90.1% respectively, p=0.58. 
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3.6.2 Rejection free survival post index biopsy by C4d score. There was no difference in all rejection 
episodes between the diffuse C4d+, focal C4d+ and C4d- groups at 88.9%, 79.0% and 79.0% 
respectively, p=0.79. 
 
 
3.6.3 AMR free survival post index biopsy by C4d score. There was no difference in subsequent 
AMR between the diffuse C4d+, focal C4d+ and C4d- groups at 100.0%, 97.4% and 90.8% 
respectively, p=0.28. 
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3.6.4 Transplant glomerulopathy free survival post index biopsy. There was no difference in 
subsequent TG between the diffuse C4d+, focal C4d+ and C4d- groups, 88.9%, 94.6% and 98.2% 
respectively, p=0.21. 
  
 
Influence of donor specific antibodies on outcomes 
Association of C4d and DSA 
22/123 [17.9%] of the C4d- patients compared with 8/48 [16.6%] of C4d+ patients had DSA at the 
time of index biopsy, p=0.97. Looking at the association between C4d scoring and DSA, 4/9 [44.4%] 
of diffusely C4d+ patients had DSA compared with 4/39 [10.3%] of focally positive patients. 
Therefore, there was a significant association between ATN with diffuse C4d and detectable DSA, 
p=0.03.  
Outcomes by DSA positivity alone 
Considering the DSA status at the time of index biopsy alone, there was no difference in allograft 
loss, however there was a tendency to increased incidence of rejection with a significant risk of 
subsequent AMR in the DSA+ group as shown in figure 3.7. 
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Figure 3.7  Allograft outcomes by DSA status 
3.7.1 Allograft survival by DSA status at the time of index biopsy. There was no difference in allograft 
loss between the DSA+ and DSA- groups with a 86.4% and 92.1% allograft survival respectively, p=0.33. 
 
3.7.2 Rejection free survival by DSA status at the time of index biopsy. There was a tendency to 
increased rejection episodes in the DSA+ group compared with the DSA- group with a 69.4% and 
81.7% rejection free survival, p=0.093. 
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3.7.3 AMR free survival by DSA status at the time of index biopsy. DSA+ patients are at higher risk 
of subsequent AMR than patients with no DSA at the time of index biopsy, with an AMR free survival 
of 79.9% and 95.6% respectively, p=0.0016. 
 
 
3.7.4 Transplant glomerulopathy free survival post index biopsy by DSA status. There was no 
difference in TG free survival which was 96.3% and 96.9% in the DSA+ and DSA- groups respectively 
at the end of follow up, p=0.21. 
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Outcomes of C4d positive ATN with DSA 
The final analysis involved a comparison of the outcomes of patients with C4d+DSA+ATN compared 
with C4d+DSA-ATN or C4d-DSA+ATN in those patients with morphological features of ATN alone on 
allograft biopsy.  
101 patients were C4d-/DSA-, 22 patients were C4d-/DSA+, 40 patients were C4d+/DSA- and 8 
patients were C4d+/DSA+ at the time of index biopsy.  
 
Risk of allograft failure 
 There was not a significant difference in allograft loss between the different groups as shown in 
figure 3.8.1. Allograft survival being 92.0%, 81.3%, 92.5% and 100.0% in the C4d-/DSA-, C4d-/DSA+, 
C4d+/DSA- and C4d+/DSA+ groups respectively, p=0.32.  
 
Risk of subsequent rejection 
Only the C4d-/DSA+ group showed a tendency to increased rejection as shown in table 3.3. Whilst 
there was no difference in the occurrence of ACR as seen in figure 3.8.2, with an ACR free survival of 
83.5%, 79.5%, 82.0% and 87.5% [p=0.94], C4d-/DSA+ patients were at significant risk of AMR as seen 
in figure 3.8.3, p=0.0004.  
 
Table 3.3 Rejection free survival by C4d and DSA status 
Group 
 
Rejection free survival [%] p value 
C4d-DSA- 
 
82.5% 0.11 
C4d-DSA+ 
 
62.8% 
C4D+DSA- 
 
79.5% 
C4D+DSA+ 
 
87.5% 
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Figure 3.8 Allograft outcomes by C4d and DSA status 
3.8.1 Allograft survival by C4d and DSA status at the time of index biopsy. There was no difference 
in allograft loss between the C4d-/DSA-, C4d-/DSA+, C4d+/DSA- and C4d+/DSA+ groups with a 
92.0%, 81.3%, 92.5% and 100.0% graft survival, p=0.32. 
 
3.8.2 ACR free survival by C4d and DSA status at the time of index biopsy. ACR free survival in the 
C4d-/DSA-, C4d-/DSA+, C4d+/DSA- and C4d+/DSA+ groups was 83.5%, 79.5%, 82.0% and 87.5% 
respectively, p=0.11. 
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3.8.3 AMR free survival post index biopsy by C4d and DSA status at time of index biopsy. AMR free 
survival in the C4d-/DSA-, C4d-/DSA+, C4d+/DSA- and C4d+/DSA+ groups was 94.8%, 72.4%, 
97.4% and 100.0% respectively, p=0.0004. 
 
3.8.4 Transplant glomerulopathy free survival post index biopsy by C4d and DSA status. There was 
no difference in TG free survival which was 100.0%, 97.8%, 94.7% and 87.5% in the C4d-/DSA-, C4d-
/DSA+, C4d+/DSA- and C4d+/DSA+ groups respectively, p=0.29. 
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Risk of transplant glomerulopathy 
At the end of follow up, there was no trend in any group towards progression to TG (the apparent 
difference in the C4d+/DSA+ group [n=8] is only a single case). It will be seen in section 5.3 that AMR 
itself carries a significant risk of subsequent TG. 
By Cox regression analysis, the DSA status at the time of index biopsy, regardless of C4d status is 
associated with subsequent AMR with typical morphological features, p=0.007. 
 
 
 
3.4 Discussion 
 
Evidence of the outcomes of patients with C4d positive ATN who have not received augmented 
immunosuppressive therapy is lacking and a retrospective study was undertaken to determine the 
natural history of such patients. It was found that C4d+ ATN was not associated with progression to 
AMR with the classical histological features of rejection when left untreated. However, patients with 
DSA+ ATN are at increased risk of AMR, with C4d- patients being at greatest risk. Focal C4d+ ATN 
was not associated with DSA however C4d was associated with DSA when co-existing with 
morphological features of rejection (data not shown in this chapter). This study has highlighted some 
important findings which have considerable management implications. Further studies are required 
in order to reproduce these findings which might prevent patients receiving an inappropriate 
immunosuppressive burden involved in the treatment of AMR.  
There is a large evidence base on the relevance of C4d staining in renal allograft biopsies, however 
the majority of C4d deposition occurs in renal allografts with co-existing classical features of 
rejection [Murata et al, 2009; Kayler et al, 2008; Coillins et al, 1999; Satoskar et al, 2008]. The clinical 
significance of C4d positivity in biopsies otherwise showing a histological diagnosis of ATN only has 
not been studied in depth. Such biopsies have been included as a subgroup in a few studies, which 
includes one by Mauyyedi and colleagues, who amongst their analysis of 20 patients with diffuse 
C4d staining found 2 patients with a histological diagnosis of ATN [Mauyyedi et al, 2002]. Only one of 
these patients subsequently developed features of AMR. Lederer’s group in their study of the 
relevance of C4d found 19 patients with ATN of which 11 had focal or diffuse C4d but they did not 
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address the outcomes in these patients [Lederer et al, 2001]. Nickelait and colleagues included in 
their analysis 11 patients with ATN of which 3 were C4d positive which was too small a number to 
determine significance; however they did highlight overall a group of C4d positive patients with 
histological findings other than rejection who had good outcomes despite not receiving augmented 
therapy [Nickelait et al, 2002]. Finally, from the same group Dickenmann went on to look at 22 
patients with C4d positive ATN and found that left untreated there was no rapid progression to 
conventional histology associated with AMR, although intervening by enhancing the 
immunosuppression in some resulted in improvement of allograft function [Dickenmann et al, 2006]. 
Once again the number studied was small and the major limitation of the study was the lack of DSA 
data. One study looking at patients receiving HLA incompatible grafts also showed that patients with 
indicative allograft biopsies demonstrating C4d positivity with minimal histological changes had 
superior outcomes when compared with those with classical morphological features of rejection 
[Rafiq et al, 2009]. 
A caveat of the interpretation of C4d positivity, regardless of the histopathological features, will 
depend upon the method of staining used, with immunofluorescence having a higher sensitivity than 
immunoperoxidase [Solez et al, 2008]. Controversy also exists between the relevance of focal C4d 
when compared with diffuse C4d staining. However there have been two studies which have looked 
at the outcomes of focal C4d determined by immunoperoxidase. They both showed that focal C4d 
was associated with circulating DSAs with one also showing a negative impact on allograft survival 
[Kayler et al, 2008; Haririan et al, 2009]. This latter study by Haririan and colleagues also showed that 
DSA status independent of C4d staining predicted allograft survival [Haririan et al, 2009] .  
It should also be considered that ATN, a common histological finding especially in the early 
transplant period, is associated with inferior allograft outcomes in its own right [Gwinner et al, 
2008]. This is thought to be due in part to the increased risk of acute rejection in histologically 
proven ATN. However ATN without subsequent rejection does not result in inferior allograft 
outcomes [Lederer et al, 2001]. Halloran et al. proposed the mechanism behind this association is 
that the ‘injury response’ triggers the ‘immune response’. It has been demonstrated that ischaemic 
injury leads to upregulation of MHC expression and an immune response [Halloran et al, 1997]. In 
cardiac transplantation, C4d is often seen early after transplant and is associated with ischaemic 
reperfusion injury and the diagnosis of AMR in cardiac allografts requires morphological features of 
rejection [Baldwin et al, 1999; Fedson et al, 2008; Moseley et al, 2010]. 
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An intriguing finding in the study is that C4d-DSA+ ATN patients are at greatest risk of subsequent 
AMR. This might be explained by considering the postulated stages of AMR described by Colvin 
[Colvin, 2007] and shown in figure 3.9. Circulating alloantibody is considered the first stage of AMR 
and only when the antibody forms a complex with its endothelial target is complement activated 
and the ‘footprint marker’ C4d detectable. So the ‘C4d-DSA+‘ status might represent an early stage 
of AMR and such patients require close monitoring with repeat allograft biopsy if there is no 
improvement clinically.  
  
   
Figure 3.9 Postulated stages of antibody mediated rejection. [Taken from Colvin, 2007] 
 
Whilst these findings suggest that the presence of C4d staining alone does not predict acute 
antibody mediated rejection, the risk of chronic antibody mediated damage is not clear, especially in 
those patients with documented donor specific antibodies, chronic antibody mediated rejection 
being recognised as one of the leading causes of allograft loss [El-Zoghby et al, 2009]. However even 
with chronic antibody mediated rejection the relevance of C4d positivity has also recently been 
questioned. Gloor and colleagues reported that in a study of 55 patients with transplant 
glomerulopathy (TG), less than a third were C4d positive, despite a strong association between the 
development of TG and class II anti-HLA [Gloor et al, 2007]. More recently Einecke et al. studied the 
phenotype of patients undergoing indication biopsies for allograft dysfunction and concluded that 
the presence of histological changes such as glomerulitis, capillaritis and glomerulopathy, along with 
anti-HLA antibodies predicited graft loss, whereas C4d staining did not [Einecke et al, 2009]. The 
same group also hypothesised that antibody mediated damage against antigens on the endothelium 
could alter gene expression, so they studied endothelial cell transcriptome expression using 
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microarrays and found that higher scores were significantly associated with the presence of donor 
specific antibody and morphological AMR whilst only 40% of these grafts were C4d+[Sis et al, 2009].  
The limitations of this study are its retrospective nature, the relatively short term follow up and the 
lack of electron microscopic [EM] findings. Further follow up of these patients will be required to 
assess the long term outcomes. A multicentre prospective study of C4d positive ATN would be the 
most appropriate next step to establish the true significance of such lesions. However, until further 
evidence is available this study shows that, in the absence of morphological features of rejection by 
light microscopy (with or without DSA), the presence of C4d staining does not predicts progression 
to the classical histopathological findings of acute AMR despite unaltered immunosuppression.  
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Chapter 4 Relevance of patients with preformed donor specific antibodies detected with 
single antigen beads in the setting of a negative crossmatch 
 
4.1 Introduction 
The development of single antigen bead assays has facilitated the identification of anti-HLA 
antibodies in sera with high sensitivity and specificity [El-Awar et al, 2005; Pei et al, 2003; Zachary et 
al, 2008]. Although previous reports suggested that these solid phase technologies are too sensitive 
for routine clinical use [Gupta et al, 2008; Vaughan et al, 2008; Patel et al, 2007], there are now an 
increasing number of studies demonstrating that, even in the circumstance of negative complement 
dependent cytotoxic [CDC] and flow cytometry crossmatches [FCXM], preformed donor specific 
antibodies are associated with inferior renal allograft outcomes [Patel et al, 2007; Amico et al, 2009; 
Gibney et al, 2006]. However there is no general consensus as to how these patients are best 
managed. The recently issued British Society of Histocompatibility and Immunogenetics/British 
Transplant Society [BSHI/BTS] guidelines state they should be managed no differently from other 
low risk patients, with no augmentation of immunotherapy [bshi.org.uk/BTS/BSHI]. This reflects the 
continued controversy over the clinical relevance of DSAs detected by solid phase techniques only, 
which is shared by transplant immunologists worldwide [Opelz et al, 2009].  
From the literarture there are no studies describing the risk of preformed DSAs in patients receiving 
antibody induction and tacrolimus monotherapy without the use of mycophenolate mofetil or more 
than one week of corticosteroids. Evidence published to date is taken from protocols using standard 
triple immunosuppressive regimens, with and without the use of induction agents [Gupta et al, 
2008; Vaughan et al, 2008; Patel et al, 2007; Amico et al, 2009]. The use of induction agents in renal 
transplantation has been shown to reduce the incidence of acute rejection, with T cells being the 
primary target for commonly used polyclonal and monoclonal antibodies [Nashan et al, 1997; 
Charpentier et al, 2003; Mourad et al, 2001]. There is now increasing evidence that B cells play a 
pivotal role in graft rejection [Zarkhin et al, 2008; Tarlinton et al, 2008]. However a randomised 
control trial using B cell directed induction therapy alone had to be prematurely terminated due to 
high rates of rejection [Clatworthy et al, 2009] and it is now believed that allograft survival is 
dependent upon both T and B cell immunomodulation [Parsons et al, 2009].  
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Alemtuzumab is a humanised anti-CD52 monoclonal antibody that has a rapid and profound 
depleting effect on both T and B lymphocytes [Bloom et al, 2006] (although not plasma cells), which 
may provide some protection in the context of crossmatch negative preformed DSAs. Alemtuzumab 
has been shown to be an effective induction agent in low risk patients [Calnet et al, 1998]. 
Furthermore, in high immunological risk patients, a randomised control trial comparing 
alemtuzumab against thymoglobulin induction showed equivalent outcomes [Thomas et al, 2007]. 
Vo and colleagues also demonstrated that alemtuzumab induction could be used in conjunction with 
desensitisation therapy in highly sensitised patients with excellent allograft survival and function [Vo 
et al, 2008]. Contradicting these outcomes are reports of an increased risk of antibody mediated 
rejection (AMR) in patients receiving alemtuzumab (22,23,24), particularly in the absence of a 
calcineurin inhibitor as maintenance immunosuppression. This described risk of AMR prompts 
questions about the role of identifiable DSAs. 
The aim of this study was to investigate the clinical relevance of preformed DSAs in patients with a 
negative CDC and FCXM receiving tacrolimus maintenance monotherapy with alemtuzumab 
induction.  
 
4.2 Methods  
480 patients who received a kidney alone transplant between 2005 and 2009 were analysed 
retrospectively. All patients had a negative crossmatch and received alemtuzumab induction. 
Baseline demographics are shown in table 4.1. Histological and immunological methods are 
described in chapter 2. 
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Table 4.1 Patient demographics 
 DSA+ 
n=45 (%) 
DSA- 
n=435 (%) 
 
p value 
 
Gender 
Female 
Male 
 
24 (53.3%) 
21 (46.7%) 
 
141(32.4%) 
294 (67.6%) 
 
 
p=0.008 
Age at transplant (years) 
 
47.15 ±11.85 47.44 ±13.14 
 
NS* 
Type of graft 
DD† 
LD‡ 
SPK 
 
17 (37.8%) 
25 (55.6%) 
3 (6.7%) 
 
196 (45.1%) 
197 (45.3%) 
42 (9.7%) 
 
 
NS 
Mean HLA mismatch 
 
 
3.96 ± 1.33 
 
 
3.26 ± 1.64 
 
p<0.01 
 
HLA mismatch summary¶ 
000 
0DR and 0/1B 
[0DR and 2B] or [1DR and 
0/1B] 
[1DR and 2B] or [2DR] 
 
 
0 (0%) 
3 (0.7%) 
18 (40%) 
 
24 (53.3%) 
 
 
42 (9.7%) 
52 (12.0%) 
172 (39.5%) 
 
169 (38.9%) 
 
0.02 
NS 
NS 
 
NS 
 
Graft number 
1st 
2nd 
3rd 
 
26 (57.8%) 
15 (33.3%) 
4 (8.9%) 
 
399 (91.7%) 
32 (7.4%) 
4 (0.9%) 
 
p<0.0001 
 
Ethnicity 
Caucasian 
Asian 
Black 
Other 
 
 
 
19 (42.2%) 
16 (35.6%) 
7 (15.6%) 
3 (6.7%) 
 
 
219 (50.3%) 
145 (33.3%) 
55 (12.6%) 
16 (3.7%) 
 
 
NS 
Mean follow up 
(years) 
1.89 ± 0.94 1.96 ± 0.97 NS 
†DD deceased donor, ‡LD living donor 
*NS= p>0.05 
¶ NHS Blood and Transplant mismatch level  
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4.3 Results 
DSAs were found in 45/480 [9.4%] of patients at the time of transplantation. A further 75/435 
[17.2%] were HLA sensitised and had non-donor specific anti-HLA antibody detected pre-
transplantation. 24/45 [53.3%] of DSA+ patients were female compared with 141/435 [32.4%] of the 
DSA- group [p=0.008]. 19/45 [42.2%] of patients with preformed DSAs were receiving a regraft 
compared with 36/435 [8.3%] of DSA- patients [p<0.0001]. There was no difference in DSA status 
between patients receiving transplants from live donors and from deceased donors. Overall the 
mean HLA mismatch was higher in the patient group with preformed DSAs [3.96 ± 1.33 and 3.26 ± 
1.64 in the DSA+ and DSA- group respectively, p<0.01]. Table 3.1 shows that 42/435 [9.7%] of the 
DSA- group had a 000 mismatch compared with 0/45 [0%] of the DSA+ group, p=0.02. A higher 
proportion of DSA+ patients [24/45 (53.3%)] had a non-favourable mismatch, which is classified as a 
[1DR and 2B] or [2DR] mismatch by the NHS Blood and Transplant organ allocation criteria in the UK 
[www.organdonation.nhs.uk], compared with 169/435 [38.9%] of DSA- patients, although this failed 
to reach statistical significance [p=0.08].  
Twenty three patients [23/45 (51.1%)] had HLA class I [CI] DSAs alone, 14 patients [14/45 (31.1%)] 
had class II [CII] DSAs alone and 8 patients [8/45 (17.8%)] had both class I and II [CI+CII] DSAs. 
Twenty nine patients [29/45 (64.4%)] had DSAs with a summed MFI > 1000 (see section 2.2 in 
chapter 2). 
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Table 4.2 List of the specificities of the DSA  and corresponding MFI 
 
Patients with Class I DSAs alone  
[n=23] 
 
Patients with Class II DSAs alone 
[n=14] 
Specificities MFI Specificities MFI 
Cw5 4680 DQ7 1723 
Cw1 979 DQ8, DQ7 2349, 600 
Cw7 1174 DR53, DQ5 2200, 2300 
B35, B7, A3 2600, 841, 300 DQ6 2472 
B57 591 DQ8 1018 
A2 800 DR53, DQ2, DQ7 3943, 700, 370 
A2, Cw1 1750, 1312 DR1, DQ5 1605, 2297 
B55, A3 1000, 900 DR12 2240 
B37 549 DQ2 1581 
B35 3200 DQ5 6500 
A30, A2 2256, 1000 DQ7 906 
B27 927 DR1, DR51 2000, 4454 
B53 756 DQ6 900 
A11,A29,B44,Cw12,Cw16 2000,1000,1000,3500, 
3500 
DQ6 772 
B62 430 Patients with both CI and CII DSAs 
[n=8] 
A11 500  
A2 364 A31, DQ2 1616, 300 
A26 600 A11, A33, DQ9 1300, 1200, 500 
B41 900 B60, DQ7 1166, 2549 
Cw5 1000 A24, DR11, DQ7 800, 4540, 2500 
B7 900 A2,Cw10,Cw5,DQ7,DQ5 600,600,550,9955,2374 
A26 3237 A2, B52, DR17, DR52 2900, 450, 3084, 547 
B62, A2, B37 1136, 750, 380 Cw1, DR13, DQ6 3300, 2088, 4806 
  A30, DR52, DQ6 4200, 750, 370 
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Patient and allograft survival 
Overall patient survival at 12 and 36 months in the DSA negative and positive groups was similar at 
98.2% and 97.5% in the DSA- and 97.8% and 97.8% in the DSA+ groups respectively [p=0.89 (log 
rank)].  
Allograft survival however was significantly inferior in the DSA+ group [p=0.047 (logrank)] as shown 
in Figure 4.1. Six DSA+ patients (6/45 [13.3%]) lost their grafts and five of these were as a result of 
rejection. 1 was lost due to donor related factors (the graft was received from a marginal donor). 
Twenty five DSA- patients (25/435 [5.7%]) lost their grafts. Twelve of these patients (12/25 [48.0%]) 
lost their graft as a consequence of rejection and eight of these patients had developed de novo DSA 
after transplantation. 13 grafts were lost due to a combination of surgical complications (2), donor 
related factors (4), renal artery stenosis (1), renal vein thrombosis (2), recurrent disease (2), 
pyelonephritis (1), haemorrhage after biopsy (1) and non-compliance (1). 
 
Figure 4.1 Comparison of allograft survival in DSA positive versus DSA negative patients. Kaplan-
Meier curve demonstrating allograft survival in the DSA+ and DSA- groups. At 12 and 36 months 
allograft survival was 91.1% and 86.7% (DSA+) and 96.3% and 94.3% (DSA-) respectively [p=0.047 
(logrank)]. 
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Rejection Episodes 
The incidence of rejection in the DSA+ patients was significantly higher than in DSA- patients. 
Acute rejection [ACR and AMR] occurred in fifteen DSA+ patients (15/45 [33.3%]) and seventy seven 
DSA- patients (77/435 [17.7%], p=0.019), [figure 4.2]. AMR was significantly more frequent in 
patients who were DSA+ at time of transplant [p<0.0001 (logrank)] as shown in figure 4.3. Twelve 
DSA+ patients (12/45 [26.7%]) compared with thirty eight DSA- patients (38/435 [8.7%]) developed 
AMR. On multivariant analysis there was no association of AMR with patients receiving regrafts 
[p=0.81] or a non-favourable mismatch [p=0.96], whereas the presence of preformed DSA was 
associated with development of AMR [p=0.006]. The mean time to the episode of AMR in patients 
with preformed DSAs was 7.4 ± 7.0 days which was earlier than the AMR occurring in DSA- patients 
[mean 198.6 ± 286.1 days, p=0.03]. The histological features and subsequent outcomes of the AMR 
episodes in the DSA+ patients are shown in table 4.3. 7/45 [15.6%] of DSA+ patients proceeded to 
develop TG compared with 12/435 [2.8%] of the DSA- patients, p<0.001. 
 
Figure 4.2 Rejection (ACR and AMR) free survival by DSA status. Kaplan-Meier curve showing all 
rejection episodes. Patients with preformed DSAs had a rejection free survival of 66.7% compared 
with 82.3% in DSA- patients, p=0.0028. 
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Figure 4.3 Antibody mediated rejection free survival by DSA status.  
Kaplan-Meier curves comparing AMR free survival in DSA+ and DSA- groups. At 1 month AMR free 
survival equals 80.0% and 96.3% in the DSA+ and DSA- patients respectively, [p=0.0002 (log rank)].  
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Table 4.3 Histological features of AMR by DSA specificities and associated outcomes. 
 
¤Banff 07; AMR I [ATN-like minimal inflammation], AMR II [Capillary ± glomerular inflammation ± 
thromboses], AMR III [arterial v3] 
§ Transplant glomerulopathy 
 
 
 
 
 
Preformed 
DSA 
specificities 
 
Preformed 
DSA  
MFIs 
De novo  
DSA 
specificites 
Histology¤ C4d TG§ Allograft 
loss 
A31, DQ2 
 
1616, 300 No AMR II Diffuse Y Y 
A11, DQ9 
 
1300, 500 A33 AMR I Focal N N 
B53 
 
3200 Cw4 AMR II Diffuse N N 
A30, A2 
 
2256, 1000 DQ4, DQ2 AMR II Diffuse Y N 
B7 
 
927 A1, DQ7 AMR II/ACR IIA Focal N N 
DQ5, DR1 
 
2297, 1605 A11 AMR II [suspicious] Negative Y N 
A24, DR11, 
DQ7 
 
800, 4540, 
2500 
B35, A3, DQ6, 
DR51 
AMR III Diffuse N Y 
B62 
 
430 B44, A11, A2, 
DQ1, DR51 
 
AMR I Diffuse N N 
A2, B52, 
DR17, DR52 
 
2900, 450, 
3084, 547 
No AMR II Diffuse Y N 
Cw1, DQ6, 
DR13 
 
3300, 4806, 
2088 
No AMR II/ACR IB Diffuse N Y 
A30, DQ6, 
DR52 
 
4200, 370, 
750 
No AMR II Diffuse Y Y 
DQ6 
 
772 No AMR I Focal N N 
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The incidence of ACR was similar in both groups of patients [ACR free survival being 88.9% and 
87.8% in the DSA+ and DSA- patients respectively, p=0.86 (logrank)]. There was a significant 
difference in the absolute lymphocyte count at the time of AMR compared with ACR in both the 
DSA+ patients [AMR: 0.28 ± 0.21, ACR: 0.77 ± 0.06, p=0.002] and the DSA- patients [AMR: 0.44 ± 
0.56, ACR: 0.82 ± 0.57, p=0.02]. However, there was no difference in lymphocyte count between the 
DSA+ and DSA- groups at the time of ACR [0.77 ± 0.06, 0.82 ± 0.57 respectively, p=0.87] and AMR 
[0.28 ± 0.21, 0.44 ± 0.56, p=0.35]. There was no difference in the tacrolimus levels at the time of 
rejection, which were 7.6 ± 4.1 in the DSA+ group, compared with 7.0 ± 3.0 in the DSA- group 
[p=0.53]. 383/480 [79.6%] of all patients remained on tacrolimus monotherapy at the end of follow 
up. 
The HLA class of the DSA associated with AMR was analysed. It was found that when compared with 
the DSA- cohort, only patients with HLA class I (CI) DSA, alone or in combination with class II DSAs 
(CI+CII) were significantly at risk of acute AMR [Figure 4.4; AMR free survival in the DSA- group was 
92.9% compared with 78.3%, 92.9% and 25% in patients with CI DSAs alone, CII DSAs alone or both 
CI+CII DSAs respectively (p=0.0072, p=0.969 and p<0.0001]. 
Figure 4.5 shows that patients who developed AMR had a higher mean MFI [4089 ±3045] compared 
with patients who did not develop AMR [2328 ±2332], p=0.046. 
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Figure 4.4 AMR free survival according to HLA class of DSA. Kaplan-Meier curves comparing AMR 
free survival in patients with no DSA, CI DSA, CII DSA and both CI+CII DSA [92.9%, 78.3%, 92.9% and 
25%], with a significance difference of p=0.0072, p=0.9685 and p<0.0001 in CI, CII and CI+CII DSA 
when compared with DSA- patients. 
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Figure 4.5 Relationship of MFI to AMR Patients who developed AMR had a significantly higher MFI 
than patients who did not have AMR [p=0.046]. The mean MFI in AMR+ patients was 4089 ±3045 
and in AMR- patients was 2328 ±2332. 
 
 
 
 
 
Allograft Function 
Figure 4.6 shows that the mean allograft function was significantly inferior after 12 months after 
transplant in the DSA+ patients when compared with the DSA- patients.  
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Figure 4.6: Comparison of allograft function in DSA+ and DSA- patients. 
Graph showing allograft function post-transplant measured by serum creatinine [µmol/l]. DSA+ 
patients had significantly inferior function when compared with DSA- patients. Serum creatinine in 
the DSA+ group was 149.56 ± 72.56, 172.14 ± 97.75 and 236.33 ± 195.43 µmol/l at 1 year, 2 years 
and 3 years after transplant compared with 127.71 ± 53.82 (p=0.06), 122.02 ± 37.62 (p<0.01) and 
127.34 ± 36.14 (p<0.01) µmol/l in the DSA- patients. 
 
 
 
Infection 
There was no difference in the incidence of BK nephropathy between the DSA+ and DSA- groups 
[3/45 (6.7%) and 12/435 (2.8%),respectively, p=0.16]. Incidence of CMV disease was low at 5/480 
[1.0%] overall with no cases in the DSA+ group. 
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4.4 Discussion 
This study shows that patients with crossmatch negative preformed DSAs receiving tacrolimus 
monotherapy following alemtuzumab induction have a high risk of AMR, impaired allograft function 
and graft loss. The occurrence of a greater degree of HLA mismatch in the DSA+ group presumably 
reflects the fact that, in patients with HLA antibodies, the greater the degree of mismatch, the more 
likely it is that the HLA antibody is donor specific. Despite alemtuzumab depleting both B and T cells, 
patients with DSAs are more likely to have early AMR when compared with those patients with no 
DSAs at the time of transplant. AMR is more common in patients with class I DSAs, whether alone or 
particularly when in combination with class II DSAs, and in patients with a higher level of antibody as 
judged by MFI.  
This study is not without precedent in patients receiving conventional immunosuppressive regimens. 
There is increasing evidence that preformed DSAs detected by single antigen [SAg] beads are 
associated with inferior allograft outcomes [Gupta et al, 2008; Patel et al, 2007; Amico et al 2009]. 
Patel et al. demonstrated that the presence of DSAs pre-transplant significantly increased the risk of 
AMR in their analysis of 20 patients [p=0.02] [Patel et al, 2007]. Gupta et al. did not find a significant 
difference in AMR rates in 16 patients, although there was a higher risk of graft loss in the DSA 
positive group (relative risk 6.5, p<0.05) [Gupta et al, 2008]. Both of these studies included patients 
receiving triple immunosuppressive regimens and although the clinical relevance of the different 
regimens cannot be determined by this study, it is an area for consideration in future work. The 
largest study to date describing the relevance of pre-transplant DSAs was published by Amico et al. 
who analysed 67 DSA+ patients and found that the rate of rejection in the positive group was 55% 
[p<0.0001] [Amico et al, 2009]. A major caveat to this study is that these patients did not have a flow 
cytometry crossmatch [FCXM] pre-transplant. T-cell FCXM positive patients have historically been 
shown to have an increased risk of AMR, although the relevance of a positive B-cell FCXM alone 
remains controversial [Delgado et al, 2008; Lefaucheur et al, 2009; Amico et al, 2009, Gebel et al, 
2003]. SAg bead assays have been shown to compare more closely with the FCXM than the CDC 
crossmatch in the ability to detect anti-HLA, although SAg bead assays are more sensitive and 
specific for anti-HLA antibody [Riethmuller et al, 2010; Amico et al, 2009]. This study is the largest to 
include patients with preformed DSAs not only with a negative CDC, but also a negative T cell FCXM.  
Importantly, whilst it was found patients with preformed DSAs had an increased risk of rejection, 
two-thirds of the patients did not develop clinical evidence of antibody mediated damage at the end 
of follow up. This suggests that the immunological risk of these crossmatch negative alloantibodies 
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need to be further refined. Determinants of the pathogenicity of preformed DSAs include the level of 
antibody, the HLA class and the complement fixing ability, which is largely dependent upon the 
immunoglobulin class and subclass [Gebel et al, 2003]. It was demonstrated that patients with DSAs 
with lower MFIs and antibody against HLA class II alone were less likely to develop acute AMR, which 
would be in keeping with published reports of patients with preformed DSA in the setting of a 
positive crossmatch [Burns et al, 2008].  
Complement fixation has been shown to be associated with AMR and it follows that the presence of 
preformed DSA able to fix complement, irrelevant of its level, will be associated with increased risk 
of rejection, which is the basis of the CDC crossmatch [Terasaki, 2003; Patel et al, 1969]. The major 
drawback of the CDC cytoxicity assay is the relative lack of sensitivity [Lefaucheur et al, 2009]. The 
flow cytometry crossmatch is more sensitive at detecting alloantibody but fails to differentiate 
between complement and non-complement fixing antibodies [Garovoy et al, 1983]. Wahrmann et al. 
have developed a technique for detecting complement fixing alloantibodies using microparticles 
[Wahrmann et al, 2009; Bohmig et al, 2008]. Applying this method to preformed DSAs may help with 
the identification of patients at higher immunological risk [Wahrmann et al, 2009]. An indirect 
approach to establishing the complement fixing ability of these low level DSAs will be to determine 
the immunoglobulin class or subclass of these DSAs [Bindon et al, 1988; Bartel et al, 2007]. Within 
the 4 subclasses of IgG, IgG3 is the most effective at fixing complement followed by IgG1 then IgG2 
and lastly IgG4 which does not fix complement [Griffiths et al, 2004; Arnold et al, 2008]. It has been 
shown that IgG1, which is the most common of the subclasses, when present in presensitised 
patients, is associated with inferior allograft outcomes in those patients who have proportionately 
higher IgG1 levels than the other subclasses [Griffiths et al, 2004]. Although far less commonly found, 
IgG3 is only required in extremely low levels to effectively fix complement [Bartel et al, 2007]. It is 
therefore hypothesised that clarifying immunoglobulin subclass of the DSA will help further quantify 
risk. 
This study shows that patients with crossmatch negative preformed DSAs receiving alemtuzumab 
induction and tacrolimus monotherapy are at significant risk of developing AMR. This is common to 
other immunosuppressive regimens and although it is not possible to draw direct comparisons, the 
use of alemtuzumab certainly does not mitigate the risk involved. Further studies are required in 
order to define the DSA characteristics associated with immunological pathogenicity as not all 
patients subsequently developed AMR. However, these results have important management 
implications having demonstrated that patients with preformed DSAs carry a significant 
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immunological risk and it is proposed that such patients should be considered for augmented 
immunosuppression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
Chapter 5 Antibody mediated rejection: incidence, risk factors and predictors of poor 
outcome 
 
5.1 Introduction 
 
Over the past decade the clinical, serological and pathological diagnosis of antibody mediated injury 
has been improving. AMR was first included as a distinct entity in the Banff classification as late as 
2001 [Racusen et al, 2003]. The current criteria include morphological evidence of tissue injury, C4d 
positivity and the detection of donor specific antibody [Sis et al, 2010]; this will continue to be 
adapted with ongoing work into the molecular markers of AMR [Reeve et al, 2009]. The ability to 
correctly diagnose acute AMR is important in order to deliver appropriate therapy and reduce 
subsequent allograft loss [Humar et al, 1999; Lefaucheur et al, 2007], acute AMR being a significant 
risk factor for the development of chronic rejection and TG [El-Zoghby et al, 2009; Issa et al, 2008]. 
There have been few studies analysing factors predictive of poor outcomes following AMR in 
immunologically low risk patients.  
The aim of this study is to analyse the incidence, time course, risk factors and outcomes of acute 
AMR in patients receiving a homogenous minimal immunosuppressive regimen. The recognition of 
factors associated with poor allograft survival will help identify a subgroup of patients who might 
benefit from novel therapeutic options.  
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5.2  Methods 
Immunosuppression regimen, treatment of rejection along with the histological and immunological 
methods are described in chapter 2.    
 
5.3  Results 
 
462 patients were retrospectively studied who received an ABO compatible, crossmatch negative 
renal transplant.  Overall, 93/462 patients [20.1%] experienced rejection, 52/462 [11.3%] developed 
ACR alone and 41/462 [8.9%] of patients had biopsy proven acute AMR (Type II or III, see table 1.2 
and section 2.4). 29/41 [70.7%] of the cases fulfilled the Banff criteria for Definite AMR (both C4d 
and DSA positive), whilst 12/41 [29.3%] were categorised as Suspicious for AMR (either C4d+ or 
DSA+ but not both). The 369/462 [79.9%] patients who remained rejection free [no AMR or ACR] 
were used as the control group.  The baseline demographics are shown in table 5.1, this shows that 
patients with preformed DSAbs and those receiving a kidney with a higher mean HLA or –DR locus 
mismatch are at increased risk of developing AMR.  11/41 [26.8%] of AMR patients had preformed 
DSAbs compared with 33/369 [8.9%] of non rejectors [NR], p=0.0012.  The mean HLA mismatch 
[A,B,DR] in the AMR group was 3.98 ± 1.19 which was significantly higher than the non rejectors who 
had a mean mismatch of 3.13 ± 1.61, p=0.001.   
The median time to rejection in the AMR group was 2.06 months [0.2 - 31.7 months] compared with 
5.77 months [0.4-44.57 months] in the patients with ACR, p=0.42.  The mean tacrolimus [FK] levels 
at the time of AMR and ACR were 7.12 ± 2.97 and 6.55 ± 2.30 respectively, p=0.34.  The absolute 
lymphocyte count was significantly higher at the time of ACR [0.8 ± 0.59 x 109/ml] than AMR  [0.55 ± 
0.53 x 109/ml], p=0.034. 
 
 
 
 
 
81 
 
Table 5.1.  Patient demographics 
  Non rejectors 
n=369 (%) 
 
AMR 
n=41 (%) 
ACR 
n=52 (%) 
p value 
Gender Male 
Female 
 
239 (64.8) 
130 (35.2) 
25 (61.0) 
16 (39.0) 
39 (75.0) 
13 (25.0) 
0.28 
Age at 
transplant  
 
Years 
 
48.54 ± 13.10 48.64 ± 12.11 45.64 ± 14.85 0.30 
Ethnicity Caucasian 
Asian 
Afrocarribean 
Other 
 
175 (47.4) 
131 (35.5) 
47 (12.7) 
16 (4.3) 
15 (36.6) 
17 (41.5) 
6 (14.6) 
3 (7.3) 
27 (51.9) 
15 (28.8) 
6 (11.5) 
4 (7.7) 
0.68 
Cause ESRF
§ 
Glomerulonephritis 
Diabetes 
APKD 
Urological 
Other 
Unknown 
 
87 (23.6) 
58 (15.7) 
55 (14.9) 
28 (7.6) 
28 (7.6) 
113 (30.6) 
11 (26.8) 
6 (14.6) 
4 (9.8) 
3 (7.3) 
1 (2.4) 
16 (39.0) 
18 (34.6) 
6 (11.5) 
8 (15.4) 
2 (3.8) 
4 (7.7} 
14 (26.9) 
0.73 
Time at ESRF 
 
Years 4.45 ± 6.0 4.38 ± 3.94 4.33 ± 5.56 0.99 
Type of graft DD* 
LURT
† 
LRT
‡ 
 
185 (50.1) 
76 (20.6) 
108 (29.3) 
23 (56.1.) 
7 (17.1) 
11 (26.8) 
27 (51.9) 
10 (19.2) 
15 (28.8) 
0.96 
Graft number First 
≥Second 
 
329 (89.2) 
40 (10.8) 
33 (80.5) 
8 (19.5) 
46 (88.5) 
6 (11.5) 
0.26 
Sensitisation Non-sensitised 
Sensitised 
Preformed DSAbs 
 
285 (77.2) 
51 (13.8) 
33 (8.9) 
23 (56.1) 
7 (17.1) 
11 (26.8) 
37 (71.2) 
10 (19.2) 
5 (9.6) 
0.0057 
HLA mismatch 
 
HLA mismatch 
level
¶ 
 
 
 
 
Follow up 
 
Mean 
 
000 mismatch 
0DR and 0/1B 
[0DR + 2B] or [1DR 
+ 0/1B] 
[1DR + 2B] or [2DR] 
 
Mean 
 
3.13 ± 1.61 
 
38 (10.3) 
52 (14.1) 
151 (40.9) 
 
128 (34.7) 
 
2.20 ± 1.25 
3.98 ± 1.19 
 
0 (0) 
1 (2.4) 
20 (48.8) 
 
20 (48.8) 
 
2.01 ± 1.17 
3.13 ± 1.84 
 
8 (15.4) 
3 (5.8) 
21 (40.4) 
 
20 (38.5) 
 
2.36 ± 1.22 
0.0059 
 
0.025 
 
 
 
 
 
0.40 
§ End stage renal failure 
*Deceased donor, †‡ Live related/unrelated renal transplant 
¶ HLA mismatch level by NHS Blood and Transplant allocation criteria 
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There was no difference in patient survival between the non rejectors, AMR group and ACR group, 
with patient survival being 95.9%, 92.7% and 96.2% respectively, p=0.61.  Allograft survival however 
was inferior in the patients who developed AMR as shown in figure 5.1, when compared with the NR 
group; allograft survival being 97.0% in the NR group and 67.4% in the AMR group, p<0.0001.  
Allograft survival in the ACR group was 84.6%, which was not statistically different from allograft 
survival in the AMR group, p=0.07.  Of the 13/41 [31.7%] patients with AMR who lost their grafts; 3 
were lost acutely during the first episode of AMR, 4 were lost due to transplant glomerulopathy [TG] 
and 6 grafts were lost due to resistant or ongoing rejection with or without complications [2 
pyelonephritis, 1 renal artery stenosis]. 
 
Figure 5.1   Effect of AMR on allograft survival.  
Comparison of patients with AMR versus those patients with no rejection [NR] and acute cellular 
rejection only [ACR].  Allograft survival being 97.0%, 84.6% and 67.4% in the NR, ACR and AMR 
respectively, p<0.001 
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Anti-HLA DSAs 
There was a highly significant association between the presence of anti-HLA DSAs and the 
development of acute AMR.  35/41 [85.4%] of patients with acute AMR had detectable DSAs 
compared with 68/369 [18.4%] of patients who did not develop acute AMR during follow up but who 
were anti-HLA DSA positive on at least one occasion, OR: 25.82 (10.44-63.84), p<0.0001.  24/35 
[68.6%] of DSAb positive AMR cases had developed their DSA de novo after transplantation, 11/24 
[45.8%] of these DSA positive cases had their antibody detected at the time of stable allograft 
function, at a median time of 5.2 months [0.53 – 17.7 months] pre rejection episode.  The risk of 
developing acute AMR following the detection of de novo DSA in the setting of stable function was 
high [OR: 3.75 (1.61-8.72), p=0.0022]. 
At the time of rejection, 6/41 [14.6%] of patients had no DSA [DSA had become undetectable in one 
of the patients with preformed DSA], 6/41 [14.6%] had class I [CI] DSA alone, 11/41 [26.8%] had class 
II [CII] DSA alone and 18/41 [43.9%] had both CI and CII DSAs.  Patients with CII DSAs at the time of 
AMR, whether alone or in combination with CI DSAs were had a tendency to increased risk of graft 
loss as shown in figure 5.2, p=0.061. 
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Figure 5.2.  Allograft survival according to diagnostic features. 
5.2.1  Allograft survival by presence or absence of class II DSA.  Patients with HLA CII DSAs at the 
time of index biopsy showed a trend to increased risk of graft loss [p=0.061] 
 
5.2.2  Allograft survival by C4d staining.  Patients with diffuse C4d had a tendency to inferior 
outcome [p=0.07] 
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5.2.3  Allograft survival by histological grade of AMR.  There is a tendency to inferior outcome with 
histological features of vascular involvement [p=0.11] when compared with those patients with 
features of glomerular or peritubular inflammation only. [Type II AMR = glomerular/capillary 
inflammation, Type II  AMR = arterial lesion]. 
 
 
Analysis of the impact of MFI, using both the cumulative and the immunodominant value, revealed a 
significant association with outcomes as shown in figure 5.3. The mean cumulative MFI in the group 
without rejection, in the AMR with graft survival group and in the AMR with allograft loss group 
were 1944 ± 2378, 5304 ± 5591 and 9278 ± 9382 respectively, p<0.001.  Similarly, the MFI of the 
immunodominant DSAb in each group was 1512 ± 1623, 2711 ± 1912 and 4108 ± 2794 respectively, 
p<0.001.  The presence of persistent DSAs after treatment was also associated with a trend to higher 
risk of allograft failure.  11/13 [84.6%] graft losses had persistent DSAs after treatment, OR: 3.14 
(0.55-17.89), p=0.20.  
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Figure 5.3  Outcome by cumulative MFI and the MFI of the immunodominant DSA  Comparison of 
patients with DSAs and no rejection [AMR-], AMR with DSAs and graft survival [AMR+] and AMR with 
DSAs and graft failure [AMR+GL]. 
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C4d staining  
34/41 [82.9%] of patients treated for AMR had focal C4d or diffuse C4d.  37/140 [26.4%] of non 
rejectors had C4d on an indication biopsy, therefore C4d was significantly associated with acute 
AMR, OR: 13.52 (5.52-33.13), p<0.0001.  Of the AMR patients, 11/41 [26.8%] had focal C4d and 
23/41 [56.1%] had diffuse C4d, whilst only 11/140 [7.9%] and 26/140 [18.6%] of the non rejectors 
had diffuse or focal C4d respectively. Diffuse C4d was highly significantly associated with AMR, OR: 
14.98 (6.27-35.82), p<0.0001, whilst focal C4d was not OR: 1.61 (0.71-3.62), p=0.25. 
The presence of diffuse C4d staining on the index AMR biopsy was associated with a tendency to 
inferior allograft survival, p=0.061 as shown in figure 5.2.  There was no difference in outcome in 
those with focal C4d staining when compared with negative C4d, p=0.80.   
 
Histological features 
25/41 [61.0%] of patients had capillary and/or glomerular inflammation and/or thrombosis [type II 
AMR] and 16/41 [39.0%] of patients had arterial involvement [type III AMR].  There was a trend to 
inferior outcomes in patients with Type III AMR (arteritis) with 7/16 experiencing allograft failure, 
compared with 6/25 patients with Type II AMR, giving an allograft survival rate of 55.0% and 75.6% 
respectively, p=0.17 as shown in figure 5.2.3.  
Patients with all 3 Banff criteria for AMR; DSA, C4d positivity and morphological features of rejection 
did not have inferior allograft survival compared with those cases which were suspicious for AMR 
only, having morphological evidence with either C4d or DSA as shown in figure 5.4.  11/29 [37.9%] of 
patients with definite AMR lost their graft compared with 2/12 [16.7%] of patients with suspicion 
only. 
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Figure 5.4.   Allograft survival by full Banff criteria of AMR versus ‘suspicious for AMR’.  
Suspicious for AMR is defined as histological evidence of tissue injury with either C4d or DSAs.  
Allograft in the full AMR criteria compared with suspicious for AMR criteria was 62.1% and 81.5% 
respectively, p=0.23. 
 
 
 
Other poor prognostic factors 
Allograft function 
5/41 [12.2%] patients were dialysis dependent at the time of the diagnosis of AMR, 2 of these 
patients subsequently lost their grafts, p=0.64.  Comparison of allograft function at the time of 
diagnosis showed no difference in the patients whose graft subsequently failed or survived [serum 
creatinine in those with graft loss: 314.4 ± 148.0, no graft loss: 273.8 ± 99.0 µmol/l, p=0.34]. 
However, patients who lost their grafts had inferior function after treatment: serum creatinine after 
treatment in those with subsequent graft loss was 364 ± 151.1, compared with 197.6 ± 116.2 µmol/l 
in patients whose grafts were still functioning at the end of follow up, p=0.0015. 
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Further AMR episodes 
10/41 [24.4%] patients had more than one episode of acute AMR, of which 6/10 [60.0%] 
subsequently lost their graft.  6/31 [19.4%] of patients with a single episode of AMR lost their graft, 
and allograft survival in these patients was superior to those with ≥2 episodes of AMR, p=0.04.  
 
Transplant glomerulopathy 
16/41 [39.0%] of patients with acute AMR developed TG, which was significantly higher than the 
patients with no rejection, of whom only 5/369 [1.4%] patients had TG, OR: 46.2 (15.65-136.47), 
p<0.0001.  As yet, there is no difference in allograft survival between the AMR patients who 
subsequently developed TG when compared with those with no TG following AMR, OR: 0.97 (0.25-
3.73), p=0.96. However, longer follow up will be required to establish the full effects.  
 
5.4 Discussion 
 
 
In this large study, an analysis has been performed of the risk factors and outcomes of acute AMR in 
patients receiving a homogenous minimal immunosuppressive regimen. AMR is not uncommon and 
is associated with inferior allograft survival.  
The incidence of AMR has been reported to be between 4-8% in immunologically low risk patients 
[Kirk et al, 2003; Singh et al, 2009]. There have been concerns that there is an increased incidence of 
rejection with a humoral component in patients receiving alemtuzumab induction [Knechtle et al, 
2003; Flechner et al, 2005]. However, these findings appear to be limited to patients receiving CNI 
free immunosuppressive regimens. Knechtle et al. in a pilot study of 29 patients using alemtuzumab 
induction and sirolimus monotherapy reported 25% of the patients experiencing rejection which was 
predominantly antibody mediated [Knechtle et al, 2003]. Flechner et al. then introduced MMF along 
with sirolimus in their study of 22 patients, however there was still an unacceptable rate of rejection 
[8/22 (36.8%)] and 2 of these episodes were antibody mediated [Flechner et al, 2005]. Reassuringly, 
randomised control trials [RCT] involving alemtuzumab induction with maintenance CNI, have failed 
to show a higher incidence of rejection than other standard regimens. Three RCT trials which include 
CNI monotherapy following alemtuzumab induction have demonstrated excellent medium term 
outcomes [Margreiter et al, 2008; Vathsala et al, 2005; Thomas et al, 2007]. Watson et al. have 
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further shown that such protocols also produce good long term outcomes, with no increase in 
rejection episodes [Watson et al, 2005].  
The development of de novo DSAs has been shown to be associated with AMR and allograft loss, and 
therefore monitoring for DSAs after transplant can help with the early identification and diagnosis of 
AMR [Zhang et al, 2005]. The reported incidence of de novo DSAs after renal transplant is highly 
variable, ranging from 5.5-24.2%, in cohorts not only receiving different immunosuppressive 
regimens but also using different screening methods [Hourmant et al, 2005, Akalin et al, 2006]. 
There are few studies describing the development of DSAs in patients receiving alemtuzumab 
induction. Cai et al. in a study into anti-HLA antibody production with alemtuzumab induction and 
sirolimus maintenance, showed 6/24 [25%] patients developed DSAs of which 4 had biopsy proven 
AMR [Cai et al, 2004]. Shapiro et al.used a protocol for weaning tacrolimus monotherapy whilst 
monitoring for the development of DSA. They found that 15% of stable patients developed DSAs on 
weaning the dose of tacrolimus [Shapiro et al, 2008]. The data showing that 17.7% of patients 
develop DSAs after transplant and that 52.7% of these patients develop AMR are consistent with 
these reports, with an overall incidence of AMR of 10.2%. 
DSAs are not only important in predicting AMR but they may also be used to guide the management 
of rejection. This study has shown that higher levels of DSA [as judged by MFI] at the time of AMR 
are associated with graft loss and that their persistence may be associated with graft failure and 
these findings are consistent with those of other authors [Everly et al, 2010; Everly et al, 2009]. 
Patients with high and persisting DSAs may benefit from either more aggressive therapy or novel 
agents.  
Whilst diffuse C4d staining has been found to be an indicator of AMR [Cai et al, 2011; Mauiyyedi et 
al, 2002], the significance of focal C4d has been more controversial [Magil et al, 2006; Nickeleit et al, 
2002]. Staining is dependent upon the technique used, with immunohistochemistry being less 
sensitive than immunofluroscence [Solez et al, 2008]. Lefaucheur and colleagues did not find an 
association between C4d and poor outcome in AMR [Lefaucheur et al]. A strong correlation of 
diffuse C4d staining with AMR was found. It should be stressed however that the majority of cases of 
AMR were associated with DSAs, and therefore likely to produce C4d positivity. 
Histologically, it was found that patients with vascular involvement have a tendency to inferior 
outcome, similar to Rafiq et al, 2009. 
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Overall, it has been demonstrated that patients with the full Banff criteria of AMR have a poor 
prognosis. The lack of randomised control trials in the treatment of acute AMR means that the most 
effective management protocol is unknown. Treatments usually used include a combination of 
antibody removal with plasmapharesis [Houmant et al, 2005], intravenous immunoglobulin [Jordan 
et al, 1998], rituximab [Pescovitz et al] and optimising tacrolimus, MMF and corticosteroids [Sun et 
al, 2007]. Those patients with poor predictive factors may benefit from enhanced therapy or 
alternative agents such as bortezomib or eculizumab [Locke et al, 2009]. 
39.0% of patients who experienced AMR developed TG and approximately a third of these patients 
have subsequently lost their grafts. Gloor et al. have described how the incidence of TG increases 
over time [Gloor et al, 2007], so with longer follow up the number of patients affected in this cohort 
might increase. TG has a poor prognosis being progressive in nature and is associated with reduced 
allograft survival [Cosio et al, 2008; Cosio et al, 2005; Rostaing et al, 2009].  
In conclusion, this study shows that acute AMR is not uncommon and has an important 
consequential effect on allograft survival. Patients who have diffuse C4d, histological features 
showing vascular involvement, HLA CII DSAs, DSAs of high MFI and persistent DSAs after treatment 
are at highest risk of graft loss. Such patients might benefit from alternative therapies which are now 
available, which could be answered in the form of a multicentre randomised control trial.  
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Chapter 6 DQ donor specific antibodies: incidence, risk factors and 
association with antibody mediated rejection and transplant glomerulopathy 
 
 
6.1 Introduction 
The importance of HLA matching on the outcome of renal transplantation has been recognised for 
over 30 years with studies showing greater benefit of compatibility at the DR locus than matching at 
either the A or B locus [Ting et al, 1980; Gilks et al, 1987]. In recent years the evidence for this has 
been strengthened by studies showing that the development of de novo donor specific antibodies 
[DSAs] after transplant is associated with antibody mediated injury and allograft failure, with class II 
DSAs having a greater effect than class I [Terasaki et al, 2007]. Anti-DQ DSAs are increasingly 
recognised as the most frequently occurring class II DSA and this extends beyond renal 
transplantation to include other solid organ transplants [Worthington et al, 2003; Issa et al, 2008; 
Musat et al, 2011; Smith et al, 2011; Palmer et al, 2002]. However, the clinical relevance of de novo 
DQ DSAs has not been extensively described.  
The effect of DQ matching has not been examined using all the recent advances in histocompatibility 
and immunogenetics, historical studies having shown conflicting results [Freedman et al, 1997; Hais 
wt al, 1993; Bushell et al, 1989]. It is known that DR and DQ demonstrate a strong linkage 
disequilibrium and it was thought that matching at the DR locus would include co-existing 
compatibility at the DQ locus [Navarrete et al, 1985]. The incidence for this not being the case is not 
known. However it is recognised that DQ expression may be upregulated on endothelial cells and as 
such may be a target for DQ antibodies and their subsequent actions [Gibbs et al, 1985]. With 
chronic rejection being the leading cause of allograft loss, mechanisms which minimise 
immunological injury should be sought [El-Zoghby et al, 2009]. It can be hypothesised that 
consideration of DQ matching may improve long term outcomes.  
The aim of this study was to determine the incidence of de novo DQ DSAs and the effect on allograft 
outcomes following their development in patients transplanted at a single centre with a 
homogenous immunosuppressive regimen. It can be questioned whether matching at the –DR locus 
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is sufficient to assume simultaneous –DQ matching and whether it risks higher levels of subsequent 
de novo DQ DSAs than previously suspected. 
 
6.2 Methods 
 
An observational study was carried out of 505 patients who received a kidney alone transplant, the 
demographics of which are shown in table 5.1. All patients were included who had a negative B and 
T cell CDC crossmatch, negative T cell flow cytometry crossmatch and those who had no detectable 
DSA detected by single antigen beads pre-transplant. Only patients who received alemtuzumab 
induction were included in the analysis. Mean follow up after transplant was 30.0 ± 17.0 months. 
Immunosuppression regimen and rejection treatment along with histological and H&I methods are 
described in chapter 2. 
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Table 6.1. Patient demographics 
 
  DQ DSA+ 
[N=50 (%)] 
 
DQ DSA- 
[N=455 (%)] 
p value 
Gender Male 
Female 
35 [70.0] 
15 [30.0] 
 
313 [68.8] 
142 [31.2] 
0.99 
Age at transplant Years 47.62 ± 14.53 
 
48.43 ± 13.33 0.33 
Ethnicity Caucasian 
Asian 
Afrocaribbean 
Other 
19 [38.0] 
23 [46.0] 
5 [10.0] 
3 [6.0] 
 
217 [47.7] 
158 [34.7] 
59 [13.0] 
21 [4.6] 
0.39 
Aetiology of renal 
failure 
Glomerulonephritis 
Diabetes 
APKD 
Urological 
Other 
Unknown 
13 [26.0] 
11 [22.0] 
3 [6.0] 
3 [6.0] 
3 [6.0] 
17 [34.0] 
 
108 [23.7] 
78 [17.1] 
67 [14.7] 
29 [6.4] 
36 [7.9] 
137 [30.1] 
0.36 
Time receiving dialysis Years 3.79 ± 5.13 3.85 ± 6.10 0.94 
Type of allograft Deceased donor 
Living related 
Living unrelated 
26 [52.0] 
15 [30.0] 
9 [18.0] 
 
243 [53.4] 
126 [27.7] 
86 [18.9] 
0.94 
Graft number 1
st
 
≥2nd 
45 [90.0] 
5 [10.0] 
 
373 [93.0] 
32 [7.0] 
0.63 
Sensitisation pre-
transplant 
Non-sensitised 
Sensitised 
44 [88.0] 
6 [12.0] 
 
373 [82.0] 
82 [18.0] 
0.38 
HLA MM Mean 3.86 ± 1.23 
 
3.17 ± 1.63 0.004 
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6.3 Results 
 
92/505 [18.2%] patients developed de novo DSAs after transplantation. 28/92 [30.4%], 41/92 
[44.6%] and 23/92 [25.0%] developed HLA class I DSAs alone, HLA class II DSAs alone or both HLA 
class I+II DSAs respectively. 50/92 [54.3%] of DSA positive patients (that is 50/505 [9.9%] of the 
overall cohort) developed a DQ DSA. 26/50 [52.0%] developed DQ DSAs along with DSAs specific for 
other loci, whilst 24/50 [48.0%] developed a DQ DSA in isolation. The distribution of DSA per HLA 
class is shown in table 6.2. 
 
Table 6.2. Distribution of DSAs 
 DSAs detected 
 
Number of patients 
N=92 [%] 
Class I DSAs alone A 
B 
Cw 
A and B 
A and Cw 
B and Cw 
7 [7.6%] 
9 [9.8%] 
6 [6.5%] 
2 [2.2%] 
2 [2.2%] 
2 [2.2%] 
 
Class II DSAs alone DR 
DQ 
DR and DQ 
 
11 [12.0%] 
25 [27.2%] 
5 [5.4%%] 
Class I+II DSAs A and DQ 
A and DR 
A and DQ,DR 
A,B and DQ 
A,B and DQ,DR 
A,B,Cw and DQ,DR 
A,Cw and DQ,DR 
B and DQ 
B and DR 
B and DQ,DR 
B,Cw and DQ 
B,Cw and DQ,DR 
Cw and DQ 
Cw and DQ,DR 
 
3 [3.3%] 
1 [1.1%] 
1 [1.1%] 
3 [3.3%] 
2 [2.2%] 
2 [2.2%] 
2 [2.2%] 
2 [2.2%] 
2 [2.2%] 
1 [1.1%] 
1 [1.1%] 
1 [1.1%] 
1 [1.1%] 
1 [1.1%] 
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Allograft outcomes in DQ DSA positive patients 
35/505 [6.9%] of patients experienced allograft failure. 12/50 [24.0%] of DQ DSA positive patients 
lost their graft, compared with 2/42 [4.8%] of the non-DQ DSA positive patients and 21/413 [5.1%] 
of DSA negative patients. Patients with DQ DSAs were at significant risk of allograft loss when 
compared to patients with non-DQ DSAs [OR 6.15 (1.29-29.30), p=0.023] or no DSAs [OR 5.89 (2.69-
12.91), p<0.0001].  
There was a significant association between DQ DSAs and AMR. 23/50 [46.0%] of DQ DSA+ patients 
had biopsy proven AMR compared with 6/42 [14.3%] of the non-DQ DSA+ group and 7/413 [1.7%] of 
DSA- patients, giving an OR of 5.11 (1.83-14.28), p=0.0019 and 49.41 (19.47-125.40) respectively, 
p<0.0001. ACR occurred in 15/50 [30.0%] of DQ DSA+ patients, 8/42 [19.0%] of non-DQ DSA+ 
patients and 56/413 [13.6%] of DSA- patients. Therefore whilst DQ DSAs were not significantly 
associated with ACR when compared with non-DQ DSA+ patients [OR 1.82 (0.68-4.85), p=0.23], 
there remained a positive association with ACR when compared with the DSA- group [OR 2.73 (1.40-
5.32), p=0.0032]. 15/50 [30.0%] DQ DSA+ patients had biopsy proven transplant glomerulopathy 
[TG] compared with 3/42 [7.1%] of non-DQ DSA+ patients and 6/413 [1.5%] of DSA- patients giving 
an OR of 5.57 (1.49-20.88), p=0.011 and 29.07 (10.61-79.64), p<0.0001 respectively.  
Table 6.3 shows a univariant analysis of the association of allograft outcomes with DSAs of different 
specificities. DSAs of all specificities are associated with AMR , TG and allograft loss. Only DQ DSAs 
were associated with ACR. On multivariant analysis, DQ DSAs were the only specificity associated 
with all of ACR, AMR, TG and allograft failure, as shown in table 6.4. 
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Table 6.3 Univariant analaysis of association of DSA specificities and allograft outcomes 
DSA Graft loss AMR ACR TG 
 OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value 
A  3.56 (1.26-10.22)  0.017 13.31 (5.55-31.98) <0.0001 1.67 (0.65-4.30) 0.29 10.01 (3.71-27.02) <0.0001 
B  5.6 (2.19-14.42)  0.0003 15.13 (6.38-35.87) <0.0001 1.97 (0.81-4.84) 0.14 12.16 (4.63-31.90) <0.0001 
Cw  3.05 (0.83-11.18) 0.09 20.75 (7.38-58.34) <0.0001 1.69 (0.54-5.34) 0.37 7.20 (2.15-24.07) 0.0013 
DR  4.02 (1.52-10.65)  0.005 13.29 (5.71-30.96) <0.0001 1.13 (0.42-3.06) 0.81 10.95 (4.22-28.46) <0.0001 
DQ  5.93 (2.74-12.85) 0.0001 28.96 (13.23-63.39) <0.0001 2.62 (1.35-5.07) 0.004 21.24 (8.68-51.99) <0.0001 
 
Table 6.4 Multivariant analysis of association between DSA specificities and allograft outcomes 
Outcome DSA 95% CI p value 
Graft loss DQ  1.83-8.59 0.0005 
B 0.98-6.17 0.056 
AMR DQ 6.10-27.49 <0.0001 
Cw 1.46-7.34 0.004 
A 1.04-4.89 0.04 
ACR DQ 1.40-4.30 0.0015 
TG DQ 4.28-28.56 <0.0001 
DR 0.89-6.29 0.087 
B 1.14-7.81 0.027 
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Risk factors for development of DQ DSAs 
From the patient demographics it was seen that patients who developed de novo DQ DSAs received 
a graft with a higher mean HLA mismatch. Analysing in more detail the antigen mismatches 
associated with DQ DSAs, there was no association on univariant analysis between mismatch at the 
A locus and DQ DSAs, p=0.10 [log rank] or mismatch at the B locus and DQ DSAs, p=0.68 [log rank]. 
However patients mismatched at the DR locus were at significant risk of developing DQ DSAs, 
p=0.0021 [log rank]. 
Analysing the effect of linkage disequilibrium between DR and DQ, it was found of the 505 patient 
studied, 108 [21.4%] were matched at both DR and DQ [DR+DQ+] whilst 284 [56.2%] were 
mismatched at both the DR and DQ loci [DR-DQ-]. However, 38 [7.5%] of patients were matched at 
DR but mismatched at DQ [DR+DQ-] and 75 [14.9%] were matched at DQ but mismatched at DR 
[DR+DQ-]. Therefore a total of 113 [22.4%] did not display the compatibility expected with a strong 
linkage disequilibrium. 
 
Allograft outcomes by DR and DQ mismatch 
There was no difference in censored allograft survival between the DR+DQ+, DR+DQ-, DR-DQ+ and 
DR-DQ- groups which was 92.5%, 97.4%, 93.2% and 92.5% at 5 years respectively, p=0.74. Overall 
there was no significant difference in the total rejection free survival between the subgroups which 
was 84.3%, 86.8%, 79.3% and 76.4% in the DR+DQ+, DR+DQ-, DR-DQ+ and DR-DQ- groups 
respectively, p=0.23 which is shown graphically in figure 6.1. Similarly analysing acute cellular 
rejection [ACR] there also was no difference with a 84.3%, 89.5%, 80.7% and 83.5% ACR free survival 
amongst the DR+DQ+, DR+DQ-, DR-DQ+ and DR-DQ- groups, p=0.73. However as shown in figure 
6.2, antibody mediated rejection [AMR] occurred at a significantly higher incidence in the group 
mismatched at both DR and DQ [DR-DQ-], with a AMR free survival of 88.5%, compared with 98.0%, 
97.4% and 98.6% in the DR+DQ+, DR+DQ- and DR-DQ+ groups, p=0.001. 
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Figure 6.1. All rejection free survival by DR, DQ and DR-DQ mismatch 
Rejection free survival in the DR+DQ+, DR+DQ-, DR-DQ+ and DR-DQ- groups was 84.3%, 86.8%, 
79.3% and 76.4% respectively, p=0.23 
 
Figure 6.2. AMR free survival by DR, DQ and DR-DQ mismatch 
AMR free survival in the DR+DQ+, DR+DQ-, DR-DQ+ and DR-DQ- groups was 98.0%, 97.4%, 98.6% 
and 88.5% respectively, p=0.001 
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Given the highly significant risk of AMR in the patients mismatched at both DR and DQ [DR-DQ-] the 
next analysis was of the incidence of DSAs in each of the subgroups [DR+DQ+, DR+DQ-, DR-DQ+ and 
DR-DQ-]. The results are shown in table 6.5 and there was an strong association with the production 
of DSAs in patients who are mismatched at both the DR and DQ loci [DR-DQ-] when compared to 
those mismatched at either DQ [DQ-DQ+] oor DR [DR+DQ-] alone, p=0.001. 
 
Table 6.5. Analysis of DQ and DR mismatching and corresponding DSA production 
 
  Number of patients 
[%] 
 
Corresponding DSAs 
[%] 
DQ mismatch 0 DQ MM 
1 DQ MM 
2 DQ MM 
184 [36.4%] 
250 [49.5%] 
71 [14.1%] 
 
0 
35 [70.0%] 
15 [30.0%] 
DR mismatch 0 DR MM 
1 DR MM 
2 DR MM 
146 [28.9%] 
263 [52.1%] 
96 [19.0%] 
 
0 
20 [69.0%] 
9 [31.0%] 
DR-DQ mismatch 0 DR-DQ MM 
0 DR/≥1 DQ MM 
≥1 DR/0 DQ MM 
≥1 DR/≥1DQ MM 
108 [21.4%] 
38 [7.5%] 
75 [14.9%] 
284 [56.2%] 
 
0 
2 [3.1%] 
2 [3.1%] 
60 [93.8%] 
 
 
6.4 Discussion 
This study has revealed several important findings. Firstly, there is a >20% discordance between 
matching at the DR and DQ locus. Secondly, there appears to be an enhanced immunogenicity with 
mismatching at both the DR and DQ loci, which is associated with increased risk of development of 
DSAs. Finally, DQ DSAs are the most frequently occurring HLA DSA post-transplant and are 
associated with antibody mediated rejection, transplant glomerulopathy and allograft loss. Thus, the 
study highlights the importance of DQ typing and matching in renal transplantation in defining 
immunological risk.  
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Ting and Morris were the first to show that mismatching at the DR locus correlated with poor 
allograft survival in 1978 [Ting et al, 1980]. At that time the DQ locus had not been formally defined, 
which occurred after the 9th Histocompatibility workshop in 1984 [Albert et al, 1984]. This was only 
possible with the introduction of molecular methods of HLA typing, which had previously been 
undertaken using serological and cellular methods which were unsatisfactory in distinguishing DQ 
from DR given their juxtaposition and linkage disequilibrium [Navarrete et al, 1985; www.ihwg.org]. 
Following this finding, a few studies addressed the impact of DQ matching on allograft survival. 
Bushell et al in a small study compared 25 DQ mismatched patients in a cohort of 62 patients who 
were DR matched and found no effect of independent DQ mismatching [Bushell et al, 1989]. 
Contradictory to this report, Hsia and colleagues reviewed the outcomes of 63 patients and found 
DQ matching did provide a survival benefit [Hsia et al, 1993]. However, the largest study was carried 
out in 1997 by Freedman et al; they analysed 12,050 cadaveric transplants which were serologically 
typed and found that DQ compatibility when considered in isolation did improve allograft survival 10. 
However once adjusted for other factors known to be associated with poor outcome, including DR 
mismatch, there was no overall benefit of independent matching at the DQ loci [Freed man et al, 
1997].  
The progressive refinement in the methodology of antibody identification after transplant, with the 
advent of single antigen beads, has revealed substantial evidence that the development of de novo 
donor specific antibodies is associated with inferior allograft survival [Terasaki et al, 2007]. Only in 
the past few years has it been demonstrated that the presence of class II DSAs is more detrimental 
to allograft survival [Gloor et al, 2007; Campos et al, 2006] than class I DSAs. The relevance of DQ 
DSAs has been less well studied, which in part might reflect the fact that typing for DQ is not 
required for allocation purposes. Of the published reports, Worthington et al showed that DSAs in 
the 112 patients studied were highly predictive of graft failure and antibodies to DQ were the 
commonest DSA detected [Worthington et al, 2003]. Three other studies have shown that DQ DSAs 
are the predominant DSA detected post-transplant, however they failed to show a correlation with 
either chronic antibody mediated rejection or allograft function [Kobayashi et al, 2011; Iniotaki-
Theodoraki et al, 2003; Zhu et al, 2008]. 
The detrimental consequences following detection of DQ DSAs are not restricted to renal 
transplantation. In a similar evolution of understanding, it has been established that class II DSAs and 
especially DQ DSAs are associated with graft failure in cardiac, lung and liver transplantation [Musat 
et al, 2011; Smith et al, 2011, Palmer et al, 2002, Levine et al, 2009]. Cardiac transplantation has 
been the most extensively studied of the other solid organ transplants. In a recent publication, Smith 
102 
 
et al followed 243 cardiac recipients after transplant and found that 57 patients developed de novo 
DSAs of which 41 were directed against DQ [Smith et al, 2011]. A new study has also shown that liver 
transplants, which are believed to be the most ‘tolerogenic’ of the solid organs transplanted, can 
also be damaged in association with DQ DSAs [Musat et al, 2011]. Applying the diagnostic criteria of 
tissue injury, C4d positivity and circulating DSA to liver recipients undergoing indication biopsies, 
Musat and colleagues found that over half of biopsies demonstrating rejection had a humoral 
component. Of the 43 patients studied, 27 patients were found to have DSAs of which 22 included 
DQ specificities [Musat et al, 2007].  
Now there is increasing acceptance of a potential role of DQ DSAs in antibody mediated injury, it will 
be necessary to establish the pathogenesis. It is known that mismatching a donor and recipient for 
class II HLA antigens enhances allorecognition [Afzali et al, 2007]. The beneficial role of T regulatory 
cells [Tregs] in transplantation has been the focus of major work over the past decade and it has 
been shown that Tregs specific for a renal transplant may protect it against rejection. Rodriguez et al 
showed a strong correlation between donor specific regulation and degree of DR matching, which 
was even greater in the setting of simultaneous DR and DQ matching [Rodriguez et al, 2004].  
To conclude, the use of screening for DSAs both routinely and when indicated using sensitive 
Luminex beads, has enabled a fuller appreciation of the immunological consequences of current HLA 
matching schemes. It certainly has highlighted the previously underestimated consequences of 
mismatching at the DQ locus. A full Registry analysis is now required and if findings are reproduced, 
DQ matching could be considered during the allocation process of deceased donor kidneys with the 
potential to increase allograft survival. 
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Chapter 7 Outcomes of T cell mediated rejection with a humoral component 
 
 
7.1 Introduction 
 
Allograft survival has not significantly changed over the past few decades [Lamb et al, 2011], but 
although rejection remains the leading cause of allograft failure [El-Zoghby et al, 2009], there has 
been a change in the type of rejection associated with graft loss [Stegall et al, 2011], possibly 
reflecting improvements in diagnosis and subclassifications of rejection. 
Historically, rejection has been categorised in many different ways, most commonly by its timing 
following transplantation (hyperacute, acute or chronic), the immunological mechanisms thought to 
be involved (cellular or antibody mediated) or whether there is allograft dysfunction or not 
(subclinical or clinical). Through the Banff classification, rejection treatments are defined depending 
on interpretation of the grade of rejection and whether predominantly cellular and antibody 
rejection is seen. However cellular and antibody mediated rejection are not mutually exclusive (the 
adaptive immune response results in both B and T cell activation [Janeway]).  
Allograft survival following antibody mediated rejection has been found to be inferior to cellular 
rejection [Figure 5.1]. Outcomes following ‘mixed’ rejection have not been extensively reported and 
consequently evidence on how such patients should be treated is lacking. The aim of this study is to 
determine if patients found to have cellular rejection with a humoral component, when treated in a 
conventional manner have inferior outcomes to those patients with pure cellular rejection by Banff 
criteria.  
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7.2 Methods 
 
There was a retrospective review of the biopsies and medical notes of all patients who received a 
kidney or simultaneous kidney and pancreas transplant at Imperial Renal and Transplant Centre 
between October 2005 and May 2011. All patients who had an indicative renal biopsy which had 
histological features of cellular rejection who subsequently received directed therapy were 
identified. Patients were excluded if receiving an antibody incompatible transplant, defined as either 
blood group incompatibility or those patients with a positive B cell CDC or T cell flow crossmatch 
who underwent desensitisation pre-transplant. Patients with Luminex positive donor specific 
antibodies [DSA] in the context of a negative crossmatch were included. Only first rejection episodes 
were analysed and separated into 4 groups as follows: 
1. Group 1. Pure TCMR 
2. Group 2. Histological TCMR with C4d positivity 
3. Group 3. Histological TCMR with DSA 
4. Group 4. Histological TCMR with C4d positivity and DSA 
Groups 2 to 4 are collectively referred to as TCMR with a humoral component or mixed TCMR. 
Patients found to have evidence of BK on their index biopsy were further excluded from the analysis. 
The patient demographics are shown in table 7.1. Patients were followed from the time of index 
biopsy to determine if there was a difference in subsequent incidence of TCMR, AMR, TG and 
allograft loss. 
Immunosuppression regimen, treatment of rejection along with histological and H&I methods are 
described in chapter 2. 
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Table 7.1 Table showing patient demographics 
  Pure group 
N=75 (%) 
Mixed group 
N=51 (%) 
 
p value 
Gender Male 
Female 
 
57 
18 
31 
20 
0.10 
 
Age at transplant Years 48.48 ± 13.66 44.88 ± 12.73 0.80 
Ethnicity Afrocaribbean 
Indoasian 
Caucasian 
Other 
 
13 
21 
36 
5 
12 
15 
24 
0 
0.79 
Aetiology of ESRF Diabetes 
APKD 
GN 
Urological 
Unknown 
Other 
 
13 
6 
22 
7 
21 
6 
3 
4 
17 
3 
9 
5 
0.52 
Time at ESRF Years 3.76 ± 4.69 5.88 ± 6.65 0.038 
RRT pre Pre-emptive 
Dialysis 
 
19 
56 
9 
42 
0.42 
Type of donor DD 
LD 
SPK 
 
36 
32 
7 
26 
24 
1 
0.76 
Graft number 1st 
≥2 
 
69 
6 
36 
15 
0.0035 
Induction Daclizumab 
Alemtuzumab 
 
12 
63 
17 
34 
0.04 
HLA mismatch  3.24 ± 1.84 3.53 ± 1.46 0.35 
Pre-sensitisation Non-sensitised 
HLA antibodies 
DSA  
 
59 
15 
1 
25 
9 
17 
0.0011 
UKT mismatch 000 
0DR + 0/1 B 
0DR +2B; 1DR +0/1 B 
1DR + 2B; 2DR 
 
10 
6 
32 
27 
1 
4 
26 
20 
0.17 
Time to rejection Months 10.72 ± 11.36 10.98 ± 12.53 0.90 
Follow up Months 25.38 ± 17.09 27.45 ± 16.24 0.50 
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7.3 Results 
149/817 [18.24%] of patients were found to have a histological diagnosis of TCMR. 15 cases occurred 
following previous biopsy proven AMR and were excluded, as were 8 patients with co-existing BK 
nephropathy, which resulted in 126 index cases remaining; 75 patients had pure TCMR, 10 cases had 
C4d+ TCMR, 30 cases had DSA+ TCMR and 11 patients had C4d+DSA+ TCMR. The distribution of 
patients within the mixed group is shown in table 7.2. 
Patients with TCMR with a humoral component were more likely to be sensitised, receiving a re-
graft and having spent a longer time at end stage renal failure. 59/75 [78.67%] of the pure group 
were non-sensitised compared with 25/51 [49.02%] of the mixed group, p=0.0011. The mean time 
spent at end stage renal failure in the pure group was 3.76 ± 4.69 years compared with 5.88 ± 6.65 
years in the mixed group. 69/75 [92.0%] of the pure group but only 36/51 [70.59%] of the mixed 
group were receiving their first allograft, p=0.0035. A higher proportion of the daclizumab group had 
mixed rejection [17/29 (58.62%)] than the alemtuzumab induced group [34/97 (35.05%)], p=0.04.  
 
 
 
 
 Table 7.2 Distribution of patients per cellular rejection category  
 
 
 
 
 
 
 
 
 
 
Group Number of patients 
126 (%) 
 
Pure ACR 
 
75 (59.5%) 
TCMR with C4d positivity 
 
10 (7.9%) 
TCMR with DSA positivity 
 
30 (23.8%) 
TCMR with C4d and DSA positivity 
 
11 (8.7%) 
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Allograft survival 
 
There was a tendency to inferior allograft survival in the patients in the mixed group when compared 
with the pure group. Allograft survival in the pure group was 89.3%, with 8/75 (10.67%) patients 
subsequently losing their grafts compared with 77.4% allograft survival in the mixed group [11/51 
(21.5%) grafts were lost], p=0.072 [Figure 6.1]. Causes of graft loss in the pure group were: 4 were 
secondary to rejection, defined by recurrent TCMR episodes with progressive scarring, 1 had to 
undergo immunosuppression withdrawal due to sepsis and subsequently died, 1 had complications 
of obstruction/urosepsis, 1 had recurrent rejection with de novo glomerulonephritis and only 1 had 
rejection with signs of chronic antibody mediated rejection. In the mixed group: 2 patients had 
recurrent rejection with pyelonephritis, 1 had complications following nephrostomy for obstruction, 
1 had recurrent disease, 1 had de novo glomerulonephritis and 6 had chronic antibody mediated 
rejection. Therefore, in the pure group recurrent rejection appeared to evolve as progressive 
scarring, compared with the mixed group who appeared to develop glomerular involvement and 
signs of chronic antibody mediated rejection or transplant glomerulopathy.  
 
Figure 7.1. Allograft survival post index biopsy in pure TCMR versus mixed TCMR. Allograft survival 
in the pure group was 89.3%, compared with 77.4% allograft survival in the mixed group [p=0.072] 
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Separating the mixed group by the manifested humoral component (i.e. C4d and/or DSA positive), 
compared with the pure group, patients with C4d positivity and DSA were more likely to experience 
graft failure with an allograft survival of 89.3% and 63.6% respectively, p=0.014 as shown in figure 
7.2. 4/11 [36.36%] of C4d DSA positive TCMR subsequently lost their grafts, all as a result of 
rejection. 
 
 
Figure 7.2. Allograft survival post index biopsy according to humoral component of TCMR 
Allograft survival in the pure group was 89.3% and 63.6% in the C4d+DSA+ TCMR group, p=0.014. 
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Recurrent rejection episodes  
 
There was no difference between the pure and mixed groups with respect to further rejection 
episodes of all types, total rejection free survival being 52.3% in the pure group and 49.4% in the 
mixed group, p=0.49. There was also no difference in recurrent TCMR episodes, with a cell mediated 
rejection free survival of 61.2% in the pure group and 65.5% in the mixed group, p=0.75. However, 
AMR occurred significantly more in the mixed group, the AMR free survival after index biopsy in the 
pure group being 93.2% and 73.7% in the mixed group, p=0.0021 as shown in figure 7.3. 
 
Figure 7.3. AMR free survival post index biopsy in the pure compared with the mixed groups. 
There was a significant risk of subsequent histologically diagnosed AMR in the mixed group when 
compared with the pure group. AMR free survival after index biopsy was 73.7% in the mixed group 
and 93.2% in the pure group, p=0.0021. 
 
 
 
110 
 
Patients with C4d and DSA positive TCMR were at highest risk of developing classical AMR, with a 
AMR free survival of 45.5% compared with 93.2% in the pure group, p<0.0001 as shown in figure 7.4. 
C4d positive, DSA negative TCMR and C4d negative, DSA positive TCMR had an AMR free survival of 
78.7% and 83.2%, p=0.15 and p=0.088 respectively. 
 
Figure 7.4 AMR free survival post index biopsy according to extent of humoral involvement. 
AMR free survival in the pure, C4d+DSA-, C4d-DSA+ and C4d+DSA+ groups were 93.2%, 78.7%, 83.2% 
and 45.5% respectively. There was a significant risk of AMR in the C4d+DSA+ TCMR when compared 
with the pure group, p<0.0001.  
  
 
Transplant glomerulopathy 
 
Patients with mixed TCMR also had a higher incidence of subsequent transplant glomerulopathy [TG] 
than the pure group. In this study the diagnosis of TG was only made at indicative biopsy in the 
setting of allograft dysfunction and/or proteinuria. TG free survival was 90.3% and 74.2% in the pure 
and mixed groups, p=0.0169. As in the case of AMR, the risk was highest in those patients with both 
C4d and DSA at the time of index biopsy, as is shown in figure 7.5.  
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Figure 7.5. TG free survival post index biopsy by humoral involvement of TCMR. 
Transplant glomerulopathy free survival in the pure, C4d+TCMR, DSA+TCMR and C4d+DSA+TCMR 
was 90.3%, 76.2%, 79.2% and 58.3% respectively, p=0.0169 
 
  
 
Glomerulitis 
31/126 [24.6%] of TCMR (all cases) had T cell dominant glomerulitis. Glomerulitis was not associated 
with C4d staining, with only 4/31 (12.90%) of the T cell glomerulitis biopsies being C4d positive, 
compared with 17/95 (17.89%) TCMR biopsies with no glomerulitis, p=0.59. T cell glomerulitis was 
also not associated with the presence of DSAs; 11/31 (35.48%) biopsies with T cell glomerulitis had 
DSA compared with 29/95 (30.53%) biopsies with no glomerulitis, p=0.77.  
Glomerulitis on univariant analysis was not associated with subsequent AMR, with an AMR free 
survival of 80.6% in the patient group with glomerulitis compared with 86.8% in the patient group 
with no glomerulitis, p=0.38. However, T cell glomerulitis was associated with increased risk of TG, 
with the TG free survival being 61.3% and 92.0% in the glomerulitis positive and negative groups 
respectively, p<0.0001. However at the time of calculation, allograft loss was not inferior in the 
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glomerulitis positive groups compared with the negative group, being 90.3% and 82.7% respectively, 
p=0.31. 
 
Multivariant analysis of factors associated with adverse clinical outcomes 
In order to determine the factors at the time of index biopsy associated with AMR, TG and allograft 
loss, a Cox-proportional hazard model was used considering factors which were significant on 
univariant analysis, namely C4d positivity, DSA, glomerulitis and patients with C4d positive DSA 
positive TCMR.  Results are shown in table 7.3. 
 
Table 7.3.  Multivariant analysis of humoral features associated with histological TCMR and 
subsequent outcome.  
 
Outcome TCMR status HR (95% CI) p value 
Graft loss C4d+DSA+ TCMR 1.47 (1.02-2.12) 0.039 
AMR C4d+DSA+ TCMR 1.86 (1.34-2.58) <0.001 
TG DSA+ TCMR 
 
3.32 (1.37-8.24) 0.01 
Glomerulitis+TCMR 5.47 (2.16-13.85) <0.001 
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7.4 Discussion 
 
It was found that TCMR with a humoral component had inferior allograft outcomes when compared 
with patients with pure TCMR. Patients with C4d positive DSA positive TCMR were at risk of 
subsequent allograft failure, morphological AMR and TG. These results have important management 
implications as TCMR with a humoral component might have a better prognosis when treated with 
immunotherapy directed at both B and T cells. 
The Banff classification of TCMR is defined as the presence of interstitial inflammation (i-score ≥2; 
>25% of parenchyma affected), tubulitis (t-score ≥2; foci of moderate tubulitis) with or without 
intimal arteritis (v-score ≥0) [Solez et al, 2008]. By immunophenotyping the infiltrating cells consist 
of either T cells and/or macrophages/monocytes with only a small fraction of B cells [Sementilli et al, 
2010]. Historically studies have demonstrated that the prognosis of allografts with TCMR is 
dependent upon the grade of rejection and arterial involvement. Nickeleit et al, looked specifically at 
arterial lesions in patients undergoing acute cellular rejection and found that those patients with 
vascular involvement were more likely to be steroid unresponsive and those with fibrinoid necrosis 
lost their grafts at 1 year despite augmented therapy with OKT3/ATG [Nickeleit et al, 1998]. Haas et 
al compared the outcomes of patients with TCMR with mild to moderate arteritis against a group 
with TCMR with severe arteritis [Banff grade IIA versus IIB TCMR] and found that patients in the 
latter category had a worse prognosis [Haas et al, 2002]. Bates et al, in their evaluation of the 
outcomes associated with the different Banff categories, also found prognosis to be correlated with 
the degree of vascular involvement [Bates et al, 1999]. More up to date studies employing the use of 
microarrays have shown that ‘pure TCMR’ can be easily reversed regardless of vascular involvement 
or timing of rejection episode as long as it is not complicated by AMR [Mueller et al, 2007; Reeve et 
al, 2009]. Furthermore, molecular methodology is being used to look at the pathogenicity of the 
isolated vascular lesion (the ‘v’ lesion), which in the absence of tubulointerstitial inflammation does 
not display other markers of rejection [Mueller et al, 2007; Sis et al, 2010]. A Banff working group 
has subsequently been created to try to establish its relevance [Sis et al, 2010]. 
By Banff criteria acute AMR is defined as morphological evidence of acute tissue injury, C4d 
positivity and evidence of DSA. It is well established that C4d is strongly associated with DSA and 
AMR. The histological features of the acute tissue injury considered as AMR lesions include; ATN-
like, capillary and/or glomerular inflammation and/or thrombosis or arterial (v3) lesion. The v3 lesion 
is placed under both the TCMR and AMR category; however glomerulitis although categorised as an 
114 
 
AMR lesion may also be seen in TCMR. Batal et al, in an indepth analysis of glomerulitis, found 47% 
of DSA negative C4d negative TCMR and 62% of borderline rejection had co-existing glomerulitis 
[Batal et al, 2011]. Magil et al demonstrated the difference between the glomerulitis associated with 
TCMR and AMR is the infiltrating cell type, which are lymphocytes in the former and monocytes in 
the latter. 
There have been few studies which have included data on TCMR biopsies with a humoral 
component. Feucht et al have shown that C4d positivity strongly correlates with allograft loss in their 
study where the majority of grafts had combined histological features of cellular rejection and what 
was then described as vascular rejection, and a significant number also had ‘cell mediated 
interstitial’ rejection [Feucht et al, 1995]. Nickeleit et al in their analysis of 398 allograft biopsies with 
the aim to determine the diagnostic relevance of C4d, found that 43% of biopsies with ‘interstitial 
rejection’ were C4d positive [Nickeleit et al, 2002]. They treated all cases of C4d positive rejection 
(regardless of histological features) with enhanced immunosuppressive therapy (OKT3/ATG) and as a 
result they found no difference in clinical outcomes between the C4d groups. They went further to 
propose that the term acute cellular rejection should be discontinued as it does not take into 
account potential co-existing humoral mechanisms and biopsies should be reported according to 
morphological features modified to include the C4d status [Nickeleit et al, 2002].  Mauiyyedi et al 
found that the outcomes of patients with C4d positive TCMR and C4d positivity with mixed 
morphological features of AMR and TCMR correlated closely with pure C4d positive AMR [Mauiyyedi 
et al, 2002]. In more recent studies, Al-Aly et al showed that it is not uncommon for patients to 
exhibit mixed morphological features of TCMR and AMR, with inferior outcomes to the pure forms 
of either category [Al-Aly et al, 2008]. Finally Kayler et al established that even patients with focal 
C4d and TCMR might have underlying humoral involvement and steroid unresponsiveness occurred 
significantly more frequently in the focal and diffuse C4d groups irrespective of the underlying 
histological features, compared with the C4d negative group [Kayler et al, 2007]. 
It should be highlighted that in this last study as in the one outlined in this chapter, the majority of 
patients received alemtuzumab induction. It has been reported that rejection episodes following 
alemtuzumab may consist of a higher proportion of C4d positive cases. Zhang and colleagues in a 
retrospective descriptive study found that 47.2% of ACR cases following alemtuzumab were C4d 
positive [Zhang et al, 2007]. In the recently published randomised control trial assessing 
alemtuzumab compared with conventional induction (basiliximab or ATG) in patients undergoing 
early steroid withdrawal, there was a tendency to more C4d positive acute rejection episodes in the 
alemtuzumab treated arm, although this failed to reach significance [Hanaway et al, 2011]. It has 
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also been reported that the infiltrate following alemtuzumab induction in pure TCMR consists mainly 
of monocytes, although such cases respond well to corticosteroid therapy [Pearl et al, 2005]. In a 
further detailed analyses of the cellular infiltrate, patients with CD20+ B cells infiltrates have a worse  
prognosis, such infiltrates being less frequent in alemtuzumab treated patients [Hippen et al, 2005]. 
However results from this chapter’s study, like others, demonstrate the distinct pathogenesis of the 
rejection processes in the TCMR episodes that are pure compared with those that have evidence of 
humoral responses.  
It has been shown that patients with TCMR with evidence of a humoral component have inferior 
outcomes when compared with cases of pure TCMR when treated in a conventional way. Either C4d 
positive and/or DSA positive TCMR suggests that humoral along with cell mediated immune 
mechanisms are present, a conclusion that has therapeutic implications. Such patients might benefit 
from more aggressive therapies such as those used for the treatment of AMR. Given the common 
interaction of the humoral and cellular components of the immune system, the classic division of the 
categories of the Banff criteria may be an over simplification. It may be more appropriate for 
C4d+DSA+ TCMR to be categorised as AMR when deciding on therapeutic measures.  
  
 
 
  
 
 
 
 
 
 
 
 
116 
 
CHAPTER 8 SUMMARY 
 
Work from this thesis has demonstrated that HLA DSAs are associated with inferior allograft 
outcomes, whether they are detected pre-transplant or following their development de novo after 
transplantation. Testing for DSA with sensitive methods such as Luminex beads used in this study 
creates an opportunity for intervention which in turn might improve outcomes. The following 
summarises each chapter and how this may impact on clinical practice. 
1.  ATN is a common finding on indication transplant biopsies. I have shown that C4d positivity 
in the absence of DSA and morphological features of rejection is not associated with 
subsequent rejection. Conversely, ATI with detectable DSA in the setting of negative staining 
for C4d is associated with subsequent rejection. Therefore patients with DSA positive ATI 
should be considered for interval biopsy. 
2. Patients with preformed DSA even with a negative crossmatch are at significant risk of AMR, 
TG and allograft loss. Therefore such patients should be considered as high immunological 
risk and should not receive minimalist immunosuppression regimens. How the outcomes 
compare with positive crossmatch transplants has not been addressed in this thesis. 
3. The development of de novo DSAs are associated with AMR, TG and allograft loss. Whilst a 
proportion of patients will have the DSA detected at the time of or after the rejection 
episode, the majority will have DSAs detected prior to rejection occurring. Therefore routine 
screening for DSA after transplant will allow for early detection or prediction of rejection 
episodes and allow for possible augmentation of baseline immunosuppression. Whether 
such a protocol for screening and treatment will be of benefit needs formal testing. 
4. DQ DSAs are the most frequent DSA to be detected after transplantation and their presence 
is associated with AMR and TG. Patients mismatched at both DR and DQ alleles are more 
likely to develop class II DSA. It is important to know the level of DQ mismatch pre-
transplant in order to define risk, and its use in organ allocation schemes may help in 
reducing DQ DSA formation. 
5. The outcome of TCMR is dependent upon the DSA and C4d status at the time of rejection. 
Patients with ‘pure’ TCMR have a good outcome, however those with ‘mixed’ TCMR are 
more likely to develop histological features of AMR and TG in the absence of antibody 
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directed therapy. Patients with mixed TCMR might benefit from the more aggressive 
treatments conventionally used for AMR.  
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Chapter 9 Future work 
 
It is postulated that accommodation can occur either by adaption of the allograft or by changes in 
the characteristics of the donor specific antibody as discussed in chapter 2. 
The work in this thesis has shown that HLA donor specific antibodies are associated with AMR and 
allograft loss. Conversely, there are a proportion of patients who do not experience AMR despite 
high levels of circulating DSA. Future investigations planned by our department as a result of the 
work in this thesis will focus on delineating the antibody characteristics associated with 
pathogenicity and graft properties associated with accommodation as shown in figure below.  
 
Figure 9.1 Flow diagram of mechanisms of accommodation 
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Host mechanisms of accommodation: Pathogenic characteristics of donor specific antibodies 
 
1.  Complement fixing DSA 
 
Stemming from this work on HLA donor specific antibodies, an Imperial College post 
graduate student is currently analysing the complement fixing ability in-vitro of both 
preformed and de novo DSA. The technique includes incubating patient sera with single 
antigen Luminex beads and then adding human serum from a recipient with normal C4 
levels and CH50 activity. Beads are then washed and incubated with fluorescein 
isothiocyanate (FITC)-conjugated rabbit polyclonal anti-C4d antibody before being placed in 
the analyser. This method was first described by Wahrmann and colleagues [Wahrmann et 
al, 2006]. Anlaysis will then be carried out on the correlation between the complement fixing 
ability and clinical outcomes. 
 
2. DSA affinity (kinetics) 
 
Affinity is most correctly defined as the ratio of rate of association of an antibody-antigen 
complex to the rate of dissociation and can be determined using a biosensor.  
 
Blood group antibody kinetics 
 Preliminary work, by Lee and colleagues at Imperial NHS Trust, has been undertaken on the 
antibody kinetics of blood group antibodies pre and post ABOi renal transplantation [Lee et 
al, 2011]. They studied 3 patients who had received ABOi allografts, 1 had experienced early 
rejection and 2 had an uncomplicated course. Serial serum samples pre and post-transplant 
were analysed using surface plasmon resonance experiments in order to determine the 
binding kinetics of antibody to synthetic blood group A and B antigens. The off rate 
constants [koff] were calculated, reflecting how transient binding was. The higher the koff 
the lower the affinity; where affinity equals kon/koff. They found that the koff in the 2 
patients with no rejection increased post-transplant, whilst the patient with rejection had a 
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decrease in koff . They hypothesise that antibody with a falling affinity, reflected in increased 
koff, protects the graft; whilst increased affinity is associated with rejection [Lee et al, 2011]. 
Similarly, antibody affinity of anti-GBM antibodies has been shown to correlate with clinical 
outcomes [Dougan et al, 2002] in work also carried out at Imperial College. 
 
HLA DSA kinetics 
Dr Lee has been instrumental in the preparatory work for the next study. Using biotinylated 
HLA pentamers bound to a chip with streptavidin, we were able to develop an assay in which 
the kinetics of HLA antibody binding to a HLA molecule were determined. We used the 
Attana® biosensor, which uses a quartz crystal which undergoes mechanical oscillation when 
an electric potential is passed through it. The magnitude of oscillation depends on how 
much the crystal is dampened (ie the antibody load). The graph below is a pictorial 
representation of the kinetics from 4 patients with A2 donor specific antibodies. The up 
curves represent association, whilst the down curves represent dissociation. Future work 
will involve refinement of this assay and its subsequent application to characterise the 
affinity of donor specific antibodies and correlate with clinical outcomes. This potentially 
could have clinical diagnostic application. 
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Figure 9.2 Association and dissociation curves of 4 separate patients with de novo A2 DSA.  
 
 
 
 
Donor mechanisms of accommodation: Phenotype of accommodation 
 
During the work carried out in this thesis patients have been identified who might be considered to 
have accommodated. Notable are the patients who are C4d and DSA positive without the classical 
morphological features of rejection on biopsy. We plan to carry out immunohistochemical staining 
of the C4d+DSA+ATI patients looking for expression of anti-apoptotic proteins [Bcl-xL and Bcl-2] and 
make a comparison of the outcomes. As RNA is extracted from biopsy specimens, the gene 
expression for the anti-apoptotic proteins can also be tested for. This potentially can be a predictive 
tool which will enable identification of patients at risk of poor outcome. This study may also be 
applied to surveillance biopsies which show C4d positivity in patients with DSA.  
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Other related studies: 
 
1.  Clinical relevance of HLA epitope mismatching 
HLA matchmaker is a computer based algorithm devised by Duquesnoy and colleagues. The 
initial aim of the computer programme was to determine HLA compatibility at the epitope 
level as opposed to the serologically defined antigen level in sensitised patients. It was 
subsequently shown that previously considered unacceptable HLA mismatches can be 
compatible at the structural level, which is important as it opens up the opportunity of 
transplantation for those patients who are highly sensisited [Duquesnoy et al, 2001, 2008, 
2009]. 
Using the algorithm, Silva and colleagues analysed the outcomes of renal transplantation 
comparing epitope versus antigen mismatching. Although there was no difference in failure 
and rejection rates, there was a greater correlation between de novo HLA antibody 
formation and epitope mismatching compared with HLA antigen mismatching. 
Using the patient cohort studied in this thesis, it would be useful to determine: 
a.  The epitope mismatching in the patient group with preformed DSA and correlate with 
outcomes. 
b. Analyse the epitope matching in the patients who developed de novo DSA and compare 
an HLA antigen mismatched group who did not develop DSA. 
 
2. Revelance of non-HLA DSA 
The H&I laboratory have screened for MICA antibodies in all patients studied in this thesis. 
Although patients are not typed for MICA, it will be useful to look at the clinical outcomes 
associated with those patients who develop de novo MICA antibodies.  
During the work of this thesis patients were also identified who had biopsy proven AMR with 
or without C4d positivity, but had no detectable HLA DSA or non-DSA. The circulating 
antibody associated with the immune mediated damage therefore remains unknown. In 
such cases, the stored serum of the patients should be tested for an array of non-HLA 
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antibodies, including vimentin antibodies, angiotensin II type I receptor antibodies and 
endothelial cell antibodies].  
3. Variation of DSA over time 
Evidence presented in this thesis has shown that patients with preformed DSA in the setting 
of a negative crossmatch are at increased risk of AMR and allograft failure. We hypothesise 
that factors impacting outcomes include: method of sensitisation and variation of MFI over 
time. The natural history of how HLA antibody detected by solid phase methods varies in 
terms of MFI is not known. Patients with worse outcomes might have had higher MFIs on 
historic samples, sufficient even to cause a positive crossmatch. They are also more likely to 
have a definitive sensitisation event such as previous transplantation, pregnancy or 
transfusion. Understanding the precipitating event and the subsequent timeline might help 
us further in terms of defining risk.  
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